Document And Entity Information (USD $) In Millions, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Feb. 27, 2015	Jun. 30, 2014
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Registrant Name	ACURA PHARMACEUTICALS, INC
Entity Central Index Key	0000786947
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 29
Trading Symbol	ACUR
Entity Common Stock, Shares Outstanding		48,947,247

CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 774	$ 12,340
Marketable securities (Note 4)	11,322	13,733
Accounts receivable, net of allowances of $5 and $28	76	194
Accrued investment income	66	120
Inventories, net (Note 5)	304	251
Prepaid expenses and other current assets	471	629
Other current deferred assets	218	186
Total current assets	13,231	27,453
Property, plant and equipment, net (Note 6)	957	941
Deferred debt issuance costs, net of accumulated amortization of $69 and $- (Note 8)	162	231
Other assets	0	5
Intangible asset, net of accumulated amortization of $155	1,845	0
Total assets	16,195	28,630
Current liabilities:
Accounts payable	217	274
Accrued expenses (Note 7)	568	541
Accrued interest	70	0
Other current liabilities	26	5
Deferred revenue	353	287
Current maturities of long-term debt (Note 8)	1,758	0
Total current liabilities	2,992	1,107
Long-term debt, net of discount of $281 and $400 (Note 8)	7,961	9,600
Long-term portion of accrued interest	190	0
Total liabilities	11,143	10,707
Commitments and contingencies (Note 13)
Stockholders’ equity:
Common stock: $.01 par value per share; 100,000 shares authorized, 48,848 and 48,325 shares issued and outstanding at 2014 and 2013, respectively	488	483
Additional paid-in capital	366,898	366,533
Accumulated deficit	(362,321)	(349,112)
Accumulated other comprehensive income (loss)	(13)	19
Total stockholders' equity	5,052	17,923
Total liabilities and stockholders' equity	$ 16,195	$ 28,630

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $) In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Accounts receivable, net of allowances	$ 5	$ 28
Accumulated amortization, deferred finance aosts	69	0
Finite-lived intangible assets accumulated amortization	155
Long-term debt, net of debt discount	$ 281	$ 400
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000	100,000
Common stock, shares issued	48,848	48,325
Common stock, shares outstanding	48,848	48,325

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenues:
Royalty revenue	$ 4	$ 10	$ 0
Product sales, net	247	113	0
License fee revenue	500	0	0
Total revenues, net	751	123	0
Operating expenses:
Cost of sales (excluding inventory write-down)	227	114	0
Inventory write-down (Note 5)	201	250	0
Research and development	4,582	4,923	3,726
Selling, marketing, general and administrative	7,940	8,926	6,013
Total operating expenses	12,950	14,213	9,739
Operating loss	(12,199)	(14,090)	(9,739)
Non-Operating income (expense):
Investment income	198	194	79
Gain on sales of marketable securities	4	4	0
Interest expense (Note 8)	(1,212)	(9)	0
Other expense, net	0	0	(8)
Total other income (expense), net	(1,010)	189	71
Loss before income taxes	(13,209)	(13,901)	(9,668)
Provision for income taxes	0	0	0
Net loss	(13,209)	(13,901)	(9,668)
Other comprehensive income (loss):
Unrealized gains (losses) on securities	(32)	59	(40)
Total other comprehensive income (loss)	(32)	59	(40)
Comprehensive loss	$ (13,241)	$ (13,842)	$ (9,708)
Loss per share:
Basic	$ (0.27)	$ (0.29)	$ (0.20)
Diluted	$ (0.27)	$ (0.29)	$ (0.20)
Weighted average shares outstanding:
Basic	48,893	47,764	47,521
Diluted	48,893	47,764	47,521

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $) In Thousands	Total	Cashless	Restricted Stock Units (RSUs)	Common Stock	Common Stock Cashless	Common Stock Restricted Stock Units (RSUs)	Additional paid-in capital	Additional paid-in capital Cashless	Additional paid-in capital Restricted Stock Units (RSUs)	Accumulated deficit	Accumulated deficit Cashless	Accumulated deficit Restricted Stock Units (RSUs)	Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) Cashless	Accumulated Other Comprehensive Income (Loss) Restricted Stock Units (RSUs)
Beginning Balance at Dec. 31, 2011	$ 36,643			$ 453			$ 361,733			$ (325,543)			$ 0
Beginning Balance (in shares) at Dec. 31, 2011				45,320
Net loss	(9,668)			0			0			(9,668)			0
Other comprehensive income (loss)	(40)			0			0			0			(40)
Share-based compensation	1,733			0			1,733			0			0
Net distribution of common stock pursuant to restricted stock unit award plan (in shares)				827
Net distribution of common stock pursuant to restricted stock unit award plan	1			8			(7)			0			0
Common shares withheld for withholding taxes (in shares)					(5)	(296)
Common shares withheld for withholding taxes		(15)	(1,033)		0	(2)		(15)	(1,031)		0	0		0	0
Net issuance of common stock pursuant to cashless exercise of stock options (in shares)				14
Net issuance of common stock pursuant to cashless exercise of stock options	0			0			0			0			0
Issuance of common stock for exercise of stock options (in shares)				7
Issuance of common stock for exercise of stock options	9			0			9			0			0
Ending Balance at Dec. 31, 2012	27,630			459			362,422			(335,211)			(40)
Ending Balance (in shares) at Dec. 31, 2012				45,867
Net loss	(13,901)			0			0			(13,901)			0
Other comprehensive income (loss)	59			0			0			0			59
Share-based compensation	1,215			0			1,215			0			0
Warrants issued with promissory notes	400			0			400			0			0
Net distribution of common stock pursuant to restricted stock unit award plan (in shares)				826
Net distribution of common stock pursuant to restricted stock unit award plan	1			8			(7)			0			0
Common shares withheld for withholding taxes (in shares)					(1)	(321)
Common shares withheld for withholding taxes		(4)	(712)		0	(3)		(4)	(709)		0	0		0	0
Net issuance of common stock pursuant to cashless exercise of stock options (in shares)				7
Net issuance of common stock pursuant to cashless exercise of stock options	0			0			0			0			0
Issuance of common stock under “at the market” offerings, net of offering costs of $102 (in shares)				1,940
Issuance of common stock under “at the market” offerings, net of offering costs of $102	3,226			19			3,207			0			0
Issuance of common stock for exercise of stock options (in shares)				7
Issuance of common stock for exercise of stock options	9			0			9			0			0
Ending Balance at Dec. 31, 2013	17,923			483			366,533			(349,112)			19
Ending Balance (in shares) at Dec. 31, 2013				48,325
Net loss	(13,209)			0			0			(13,209)			0
Other comprehensive income (loss)	(32)			0			0			0			(32)
Share-based compensation	890			0			890			0			0
Net distribution of common stock pursuant to restricted stock unit award plan (in shares)				825
Net distribution of common stock pursuant to restricted stock unit award plan	1			8			(7)			0			0
Common shares withheld for withholding taxes (in shares)					(2)	(315)
Common shares withheld for withholding taxes		(4)	(525)		0	(3)		(4)	(522)		0	0		0	0
Net issuance of common stock pursuant to cashless exercise of stock options (in shares)				8
Net issuance of common stock pursuant to cashless exercise of stock options	0			0			0			0			0
Issuance of common stock for exercise of stock options (in shares)				7
Issuance of common stock for exercise of stock options	8			0			8			0			0
Ending Balance at Dec. 31, 2014	$ 5,052			$ 488			$ 366,898			$ (362,321)			$ (13)
Ending Balance (in shares) at Dec. 31, 2014				48,848

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash Flows from Operating Activities:
Net loss	$ (13,209)	$ (13,901)	$ (9,668)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	119	134	131
Provision to reduce inventory to net realizable value	201	250	0
Share-based compensation	890	1,215	1,733
Amortization of debt discount and deferred debt issue costs	188	0	0
Amortization of bond premium in marketable securities	250	0	0
Amortization of intangible asset	155	0	0
Gain on sales of marketable securities	(4)	(4)	0
Loss on disposal of property, plant and equipment	0	0	8
Changes in assets and liabilities
Accounts receivable	118	(194)	0
Accrued investment income	54	(84)	0
Inventories	(254)	(282)	(219)
Income taxes refundable	0	43	110
Prepaid expenses and other current assets	158	(358)	(16)
Other current deferred assets	(32)	(186)	0
Other assets	5	6	0
Accounts payable	(57)	(720)	941
Accrued expenses	27	128	(64)
Deferred revenue	66	287	0
Accrued interest - current and long term	260	0	0
Other current and non-current liabilities	21	(12)	6
Net cash used in operating activities	(11,044)	(13,678)	(7,038)
Cash Flows from Investing Activities:
Purchases of marketable securities	(2,203)	(7,611)	(20,306)
Proceeds from sale and maturities of marketable securities	4,336	13,887	320
Acquisition of product rights	(2,000)	0	0
Additions to property, plant and equipment	(135)	(23)	(147)
Net cash (used in) provided by investing activities	(2)	6,253	(20,133)
Cash Flows from Financing Activities:
Proceeds from exercise of stock options	8	9	9
Proceeds from distribution of restricted stock units	1	1	1
Statutory minimum withholding taxes paid on the distribution of common stock pursuant to restricted stock unit plan and exercise of stock options	(529)	(716)	(1,048)
Long-term debt borrowings	0	10,000	0
Capitalized debt issuance costs	0	(231)	0
Proceeds from “at the market offering”	0	3,328	0
“At the market offering” transaction costs	0	(102)	0
Net cash (used in) provided by financing activities	(520)	12,289	(1,038)
Net (decrease) increase in cash and cash equivalents	(11,566)	4,864	(28,209)
Cash and cash equivalents at beginning of year	12,340	7,476	35,685
Cash and cash equivalents at end of year	774	12,340	7,476
Cash paid (refunded) during the year for:
Interest	765	9	0
Income taxes, net of refunds	$ 14	$ (42)	$ (108)

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $) Share data in Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2014 Stock options	Dec. 31, 2013 Stock options	Dec. 31, 2012 Stock options	Dec. 31, 2014 Restricted Stock Unit	Dec. 31, 2013 Restricted Stock Unit	Dec. 31, 2012 Restricted Stock Unit
Supplemental Disclosure of Noncash Financing Activities:
Equity based employee compensation granted		24	24	24	829	829	829
Common stock withheld in exercise costs in shares		16	17	10	4	3	2
Common stock withheld in exercise costs		$ 32,000	$ 32,000	$ 31,000	$ 7,000	$ 7,000	$ 7,000
Withholding of exercise cost in shares		2	1	5	315	321	296
Minimum statutory withholding payroll taxes withheld		4,000	4,000	15,000	525,000	712,000	1,000
Common Stock issued upon exercise		6	6	9	510	505	531
Class of Warrant or Right, Outstanding	298
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.595
Amortization of Debt discount Costs	400,000
Proceeds from Issuance of Debt	$ 10,000,000

DESCRIPTION OF BUSINESS

12 Months Ended

Dec. 31, 2014

Description Of Business Disclosure [Abstract]

DESCRIPTION OF BUSINESS

NOTE 1 - DESCRIPTION OF BUSINESS

Acura Pharmaceuticals, Inc., a New York corporation, and its subsidiary (the “Company”, “We”, or “Our”) is a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Our Aversion® Technology is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules intended to address some common methods of product tampering associated with opioid abuse. Oxaydo™ Tablets (formerly known as Oxecta®) (oxycodone HCl, CII), is the first approved product utilizing Aversion in the United States and we have 7 additional opioid products utilizing Aversion in various stages of development. On January 7, 2015, we entered into a Collaboration and License Agreement with Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation (collectively, “Egalet”) pursuant to which we exclusively licensed to Egalet worldwide rights to manufacture and commercialize Oxaydo. Oxaydo is currently approved by the FDA for marketing in the United States in 5mg and 7.5 mg strengths. We are advised that Egalet plans to launch Oxaydo in the United States in the third quarter of 2015. We have also developed Impede® Technology which is a combination of inactive ingredients that prevent the extraction of pseudoephedrine from tablets and disrupt the direct conversion of pseudoephedrine from tablets into methamphetamine. We launched our first Impede Technology product, Nexafed®, into the United States market in December 2012 and our Nexafed Sinus Pressure + Pain product in the United States in February 2015. We have multiple pseudoephedrine products in development utilizing our Impede Technology. In August 2014, we received a grant from the National Institute on Drug Abuse to advance early stage development of our third abuse deterrent technology, Limitx™. Limitx is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The Company’s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The consolidated financial statements include the accounts of our wholly-owned subsidiary, Acura Pharmaceutical Technologies Inc., after elimination of intercompany accounts and transactions.

Reclassifications

Certain reclassifications have been made to the prior years' amounts to conform to the current year's presentation.

Management Estimates

Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Management periodically evaluates estimates used in the preparation of the consolidated financial statements for continued reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based on such periodic evaluations.

Cash and Cash Equivalents

The Company considers cash and cash equivalents to include cash in financial institutions and money market funds. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Our cash and cash equivalents are governed by our investment policy as approved by our Board of Directors. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature.

Marketable Securities

The Company’s marketable securities at December 31, 2014 and 2013 primarily consist of corporate debt securities and exchange-traded funds. Our marketable securities are governed by our investment policy as approved by our Board of Directors. The Company’s marketable securities are classified as available-for-sale and are recorded at fair value, based upon quoted market prices or net asset value. Unrealized temporary adjustments to fair value are included in a separate component of stockholders’ equity as unrealized gains and losses and reported as a component of accumulated other comprehensive income (loss). No gains or losses on marketable securities are realized until shares are sold or a decline in fair value is determined to be other-than-temporary. If a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established.

Fair Value of Other Financial Instruments

The Company’s financial instruments consist primarily of cash and cash equivalents, marketable securities, accounts and other receivables, trade accounts payable, accrued expenses and our long-term debt. The carrying amounts of these financial instruments, other than marketable securities and our long-term debt, are representative of their respective fair values due to their relatively short maturities. The Company believes the fair value of long-term debt approximates its carrying value based upon the borrowing rates currently available to the Company for loans with similar terms. As discussed below, marketable securities are recorded at fair value.

Concentration of Credit Risk

Credit Risk: Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents, marketable securities and accounts receivable. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. However, management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company’s excess cash is invested in accordance with the investment policy approved by our Board of Directors that seeks a combination of both liquidity and safety of principal using diversification of investments, through investments such as investment grade corporate debt securities with varying maturities. To date, the Company has not experienced any material realized losses on its cash, cash equivalents, and marketable securities.

Customers: We launched our first Impede Technology product, Nexafed®, into the United States market in December 2012. Our accounts receivable arise from our product sales of Nexafed and represents amounts due from wholesalers in the health care and pharmaceuticals industries and from chain drug stores. The Company has performed a credit evaluation of its customers and may maintain an allowance for potentially uncollectable accounts. We have not experienced any losses on uncollectable accounts from launch through December 31, 2014.

Sales to certain of our customers during 2014 and 2013 accounting for 10% or more of our annual product sales, whether the product shipment was recognized or deferred, are presented below:

Customer	2014
Rite Aid Corporation		28	%
Cardinal Health, Inc.		24	%
AmerisourceBergen Corporation		13	%
McKesson Corporation		13	%
Kroger Foods		11	%

	2013
Rite Aid Corporation		52	%
Cardinal Health, Inc.		15	%

Accounts receivable from certain of our customers at December 31, 2014 and 2013 accounting for 10% or more of our gross accounts receivable are presented below:

Customer	2014
Kroger Foods		13	%
Rite Aid Corporation		83	%

	2013
Rite Aid Corporation		95	%

Inventories

Inventories consist of both raw and packaging materials on our Oxaydo product and finished goods held for distribution and sale on our Nexafed® product. During 2014 we purchased raw and packaging material inventories for $260 thousand from Pfizer on the Oxaydo product we reacquired from them. Inventories are stated at the lower of cost (first-in, first-out method) or market (net realizable value). The Company writes down inventories to net realizable value based on forecasted demand and market conditions, which may differ from actual results.

Our purchases of active pharmaceutical ingredients and raw materials required for our development and clinical trial manufacture of product candidates utilizing our Aversion®, Impede® or Limitx Technologies are expensed as incurred.

Property, Plant and Equipment

Property, plant and equipment are stated at cost, less accumulated depreciation. We have no leasehold improvements. Betterments are capitalized and maintenance and repairs are charged to operations as incurred. When a depreciable asset is retired from service, the cost and accumulated depreciation is removed from the respective accounts.

Depreciation expense is recorded on a straight-line basis over the estimated useful lives of the related assets. The estimated useful lives of the major classification of depreciable assets are:

Building and improvements		10 - 40 years
Land and improvements		20 - 40 years
Machinery and equipment		7 - 10 years
Scientific equipment		5 - 10 years
Computer hardware and software		3 - 10 years

Debt Issuance Costs and Debt Discount

Deferred debt issuance costs include costs of debt financing undertaken by the Company, including legal fees, placement fees and other direct costs of the financing. Debt discount is the value attributable to warrants issued in conjunction with the financing. Debt issuance costs and debt discount are amortized into interest expense over the term of the related debt using the effective interest method.

Revenue Recognition

Revenue is generally realized or realizable and earned when there is persuasive evidence an arrangement exists, delivery has occurred or services rendered, the price is fixed and determinable, and collection is reasonably assured. The Company records revenue from its Nexafed® product sales when the price is fixed and determinable at the date of sale, title and risk of ownership have been transferred to the customer, and returns can be reasonably estimated.

Royalty Revenue

In connection with our License, Development, and Commercialization Agreement dated October 30, 2007 with King Pharmaceuticals Research and Development, Inc., now a subsidiary of Pfizer Inc. (the “Pfizer Agreement”), we began earning royalties on Oxecta starting in February 2013. We recorded royalties of approximately $4 thousand and $10 thousand for the years ended December 31, 2014 and 2013, respectively. Effective April 9, 2014, the Pfizer Agreement was terminated and the rights to Oxecta were returned to us after making a one-time payment of $2.0 million to Pfizer.

On January 7, 2015, we, Egalet US, Inc., Egalet Ltd., and Egalet Corporation (collectively, “Egalet”) entered into a Collaboration and License Agreement to commercialize Oxaydo™ tablets (formerly known as Oxecta) containing our Aversion® Technology. We will receive a stepped royalty at percentage rates ranging from mid-single digits to double-digits on net sales during a calendar year based on Oxaydo net sales during such year (excluding net sales resulting from our co-promotion efforts) (see Note 3).

Product Sales

Nexafed® was launched in December 2012. The Company sells Nexafed® in the United States to wholesale pharmaceutical distributors as well as directly to chain drug stores. Nexafed® is generally sold subject to the right of return beginning six months prior to and ending twelve months following the product expiration. Nexafed® currently has a shelf life of twenty-four months from the date of manufacture. Given the limited sales history of Nexafed®, the Company currently cannot reliably estimate expected returns of the product at the time of shipment to certain customers. Accordingly, the Company has deferred the recognition of revenue on $0.4 million of Nexafed® shipments to these customers until the right of return no longer exists or adequate history and information becomes available to estimate product returns.

License Fees

The Company entered into an agreement with Purdue Pharma to settle a patent interference action regarding certain intellectual property held by Acura (U.S. Patent No. 8,101,630). The dispute centered upon the issue of which company has priority in developing the invention. The parties agreed to forgo protracted litigation and the uncertainties arising therefrom by entering an agreement whereby Acura conceded Purdue’s claim of priority in exchange for certain financial consideration to us including an immediate non-refundable payment of $500 thousand.

On January 7, 2015, we and Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation (collectively, “Egalet”) entered into a Collaboration and License Agreement to commercialize Oxaydo™ tablets (formerly known as Oxecta) containing our Aversion® Technology. Egalet paid us an upfront payment of $5 million upon signing of the Egalet Agreement (see Note 3).

Advertising Costs

The Company records the cost of its advertising efforts when services are performed or goods are delivered.

Shipping and Handling Costs

The Company records shipping and handling costs in selling expenses. The amounts recorded from the sales of Nexafed® were not material.

Impairment of Long-Lived Assets

Long-lived assets such as the intangible asset and property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability of the assets to be held and used is measured by a comparison of the carrying amount of the asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying value of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. We had no impairment charges for years ended 2014, 2013 and 2012.

Research and Development Activities

Research and Development (“R&D”) expenses include internal R&D activities, external Contract Research Organization (“CRO”) services and their clinical research sites, and other activities. Internal R&D activity expenses include facility overhead, equipment and facility maintenance and repairs, laboratory supplies, pre-clinical laboratory experiments, depreciation, salaries, benefits, and share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting, and regulatory legal counsel. Internal R&D activities and other activity expenses are charged to operations as incurred. We make payments to the CRO's based on agreed upon terms and may include payments in advance of a study starting date. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the stage of completion of a study as provided by the CRO. Accrued CRO costs are subject to revisions as such studies progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. We did not have any accrued CRO costs and clinical trial study expenses at either December 31, 2014 or 2013. We had no prepaid CRO costs and clinical trial study expenses at either December 31, 2014 or 2013.

Share-based Compensation

We have several share-based compensation plans covering stock options and RSUs for our employees and directors, which are described more fully in Note 11.

We measure our compensation cost related to share-based payment transactions based on fair value of the equity or liability instrument issued. For purposes of estimating the fair value of each stock option unit on the date of grant, we utilize the Black-Scholes option-pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of our common stock (as determined by reviewing our historical public market closing prices). Our accounting for share-based compensation for RSUs is based on the fair-value method. The fair value of the RSUs is the market price of our common stock on the date of grant, less its exercise cost.

Our share-based compensation expense recognized in the Company’s results of operations comprised the following:

	Year ended December 31,
	2014		2013		2012
	(in thousands)
Research and development:
Stock option awards	$	220	$	315	$	375
RSU awards		-		-		-
	$	220	$	315	$	375

Selling, general and administrative:
Stock option awards		550		900		1,358
RSU awards		146		-		-
	$	696	$	900	$	1,358

Total share-based compensation expense	$	916	$	1,215	$	1,733

Comprehensive Income (Loss)

Comprehensive income (loss) includes all changes in equity during a period except those that resulted from investments by or distributions to the Company’s stockholders. Other comprehensive income (loss) refers to revenues, expenses, gains and losses that, under GAAP, are included in comprehensive income (loss), but excluded from net income (loss) as these amounts are recorded directly as an adjustment to stockholders’ equity. Acura’s other comprehensive income (loss) is composed of unrealized gains (losses) on certain holdings of marketable securities, net of any realized gains (losses) included in net income (loss).

Income Taxes

We account for income taxes under the liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and the income tax basis of assets and liabilities and are measured using the enacted income tax rates and laws that will be in effect when the differences are expected to reverse. Additionally, net operating loss and tax credit carryforwards are reported as deferred income tax assets. The realization of deferred income tax assets is dependent upon future earnings. A valuation allowance is required against deferred income tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets may not be realized. At both December 31, 2014 and 2013, 100% of all remaining net deferred income tax assets were offset by a valuation allowance due to uncertainties with respect to future utilization of net operating loss carryforwards. If in the future it is determined that additional amounts of our deferred income tax assets would likely be realized, the valuation allowance would be reduced in the period in which such determination is made and an additional benefit from income taxes in such period would be recognized.

Earnings Per Share (“EPS”)

Basic EPS is computed by dividing net income or loss by the weighted average common shares outstanding during a period, including shares weighted related to vested Restricted Stock Units (“RSUs”) (see Note 11). Diluted EPS is based on the treasury stock method and computed based on the same number of shares used in the basic share calculation and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and stock warrants, assuming the exercise of all in-the-money stock options and warrants. Common stock equivalents are excluded from the computation where their inclusion would be anti-dilutive. No such adjustments were made for 2014, 2013 or 2012 as the Company reported a net loss for the years and including the effects of common stock equivalents in the diluted EPS calculation would have been antidilutive.

A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following:

	Years ended December 31,
	2014		2013		2012

	(in thousands except per share data)
EPS - basic
Numerator: net loss	$	(13,209)	$	(13,901)	$	(9,668)
Denominator:
Common shares		48,847		46,935		45,863
Vested RSUs		46		829		1,658
Basic weighted average shares outstanding		48,893		47,764		47,521
EPS - basic	$	(0.27)	$	(0.29)	$	(0.20)

EPS – assuming dilution
Numerator: net loss	$	(13,209)	$	(13,901)	$	(9,668)
Denominator:
Common shares		48,847		46,935		45,863
Vested RSUs		46		829		1,658
Stock options		-		-		-
Common stock warrants		-		-		-
Diluted weighted average shares outstanding		48,893		47,764		47,521
EPS - diluted	$	(0.27)	$	(0.29)	$	(0.20)

Excluded dilutive securities:
Common stock issuable:
Stock options		4,556		3,738		3,296
Common stock warrants		298		2,154		1,856
Total excluded potentially dilutive shares		4,854		5,892		5,152

Recent Accounting Pronouncements

In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP.

The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard in 2017.

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References+ Details

LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS

12 Months Ended

Dec. 31, 2014

Research and Development Disclosure [Abstract]

LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT

NOTE 3 – LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS

Pfizer Agreement

In October 2007, we entered into a License, Development and Commercialization Agreement, or the Pfizer Agreement, with King Pharmaceuticals Research and Development, Inc., now a subsidiary of Pfizer, to develop and commercialize in the United States, Canada and Mexico certain opioid analgesic products utilizing our Aversion Technology. Aversion Oxycodone was approved by the U.S. Food and Drug Administration, or FDA, on June 17, 2011 and sales of Aversion Oxycodone, under Pfizer’s brand name Oxecta, commenced in February 2012. For sales of Aversion Oxycodone occurring on and following February 2, 2013 (the one year anniversary of first commercial sale), Pfizer paid us a royalty of 5% of net sales of Aversion Oxycodone.

On September 24, 2012, we entered into a letter agreement with Pfizer which provided for the termination of Pfizer’s license to our Aversion Technology used in three development-stage products licensed to Pfizer and for the return of these products to us. On April 9, 2014, we entered into a second letter agreement with Pfizer providing for the termination of the Pfizer Agreement and the return of Aversion Oxycodone to us effective April 9, 2014. The letter agreement further provides that (i) Pfizer will cease the development, marketing and sale of any product using our technologies effective April 9, 2014, (ii) Pfizer will retain its Oxecta® trademark, (iii) Pfizer transferred to us all studies, data, regulatory filings (including the NDA) and all other information relating to Aversion Oxycodone pursuant to a transition process described in the letter agreement, (iv) we will remit to Pfizer a one-time termination payment of $2.0 million, and (v) each party waives all claims against the other relating to the Pfizer Agreement. Pfizer’s royalty payment obligations relating to Aversion Oxycodone ceased effective April 9, 2014 and all royalty payments due to us have been received. Our termination payment of $2.0 million has been recorded on our financial statements as an intangible asset and will be amortized over the remaining useful life of the patent for Aversion Oxycodone. The recorded value of the intangible asset will be periodically assessed for impairment. We also purchased raw and packaging material inventories for $260 thousand from Pfizer on the Aversion Oxycodone product.

Egalet Agreement

On January 7, 2015, we and Egalet entered into a Collaboration and License Agreement (the “Egalet Agreement”) to commercialize Aversion Oxycodone under the tradename Oxaydo™. Oxaydo is approved by the FDA for marketing in the United States in 5 mg and 7.5 mg strengths. Under the terms of the Egalet Agreement, we are transferring the approved NDA for Oxaydo to Egalet and Egalet is granted an exclusive license under our intellectual property rights for development and commercialization of Oxaydo worldwide (the “Territory”) in all strengths, subject to our right to co-promote Oxaydo in the United States.

In accordance with the Egalet Agreement, we and Egalet have formed a joint steering committee to coordinate commercialization strategies and the development of product line extensions. Egalet will pay a significant portion of the expenses relating to (i) annual NDA PDUFA product fees, (ii) expenses of the FDA required post-marketing study for Oxaydo and (iii) expenses of clinical studies for product line extensions (additional strengths) of Oxaydo for the United States and will bear all of the expenses of development and regulatory approval of Oxaydo for sale outside the United States. Egalet is responsible for all manufacturing and commercialization activities in the Territory for Oxaydo. Subject to certain exceptions, Egalet will have final decision making authority with respect to all development and commercialization activities for Oxaydo, including pricing, subject to our co-promotion right. Egalet may develop Oxaydo for other countries and in additional strengths, in its discretion.

Egalet paid us an upfront payment of $5 million upon signing of the Egalet Agreement and will pay us a $2.5 million milestone on the earlier to occur of (A) the launch of Oxaydo and (B) January 1, 2016, but in no event earlier than June 30, 2015. In addition, we will be entitled to a one-time $12.5 million milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year. We will receive from Egalet a stepped royalty at percentage rates ranging from mid-single digits to double-digits on net sales during a calendar year based on Oxaydo net sales during such year (excluding net sales resulting from our co-promotion efforts). In any calendar year in which net sales exceed a specified threshold, we will receive a double digit royalty on all Oxaydo net sales in that year (excluding net sales resulting from our co-promotion efforts). If we exercise our co-promotion rights, we will receive a share of the gross margin attributable to incremental Oxaydo net sales from our co-promotion activities. Egalet’s royalty payment obligations commence on the first commercial sale of Oxaydo and expire, on a country-by-country basis, upon the expiration of the last to expire valid patent claim covering Oxaydo in such country (or if there are no patent claims in such country, then upon the expiration of the last valid claim in the United States or the date when no valid and enforceable listable patent in the FDA’s Orange Book remains with respect to Oxaydo. Royalties will be reduced upon the entry of generic equivalents, as well for payments required to be made by Egalet to acquire intellectual property rights to commercialize Oxaydo, with an aggregate minimum floor.

The Egalet Agreement expires upon the expiration of Egalet’s royalty payment obligations in all countries. Either party may terminate the Egalet Agreement in its entirety if the other party breaches a payment obligation, or otherwise materially breaches the Egalet Agreement, subject to applicable cure periods, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. We also may terminate the Egalet Agreement with respect to the U.S. and other countries if Egalet materially breaches its commercialization obligations. Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalet’s launch of Oxaydo. Egalet also may terminate the Agreement prior to the launch of Oxaydo on 30 days prior written notice upon the occurrence of serious safety issues, regulatory restrictions and intellectual property issues, in each case involving Oxaydo. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Egalet Agreement provides for the transition of development and marketing of Oxaydo from Egalet to us, including the conveyance by Egalet to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Egalet’s supply of Oxaydo for a transition period.

Paragraph IV ANDA Litigation

On or about September 17, 2012, we believe the FDA internally changed the status of Oxecta® to be considered a Reference Listed Drug, or RLD. An RLD is the standard to which all generic versions must be shown to be bioequivalent and a drug company seeking approval to market a generic equivalent must refer to the RLD. By designating Oxecta® as an RLD, the FDA was allowed to accept ANDAs referencing Oxecta®.

On September 20, 2012, we announced that we had received a Paragraph IV Certification Notice under 21 U.S.C. 355(j) (a Paragraph IV Notice) from a generic sponsor of an ANDA for a generic drug listing Oxecta® as the reference listed drug. Since such date, we have received similar Paragraph IV Notices from four other generic pharmaceutical companies that have filed ANDAs listing Oxecta® as the reference drug. The Paragraph IV Notices refer to our U.S. Patent Numbers 7,201,920, 7,510,726 and 7,981,439, which cover our Aversion® Technology and Oxecta®. The Paragraph IV Notices state that each generic sponsor believes that such patents are invalid, unenforceable or not infringed. On October 31, 2012, we initiated suit against each of Watson Laboratories, Inc. – Florida (Watson), Par Pharmaceutical, Inc., Impax Laboratories, Inc. and Sandoz Inc., and on April 29, 2013 we initiated suit against Ranbaxy, Inc., each in the United States District Court for the District of Delaware alleging infringement of our U.S. Patent No. 7,510,726 listed in the FDA’s Orange Book. The commencement of such litigation prohibits the FDA from granting approval of the filed ANDAs until the earliest of 30 months from the date the FDA accepted the application for filing, or the conclusion of litigation. In January 2013, we dismissed our suit against Watson on the grounds that Watson had amended its ANDA from a Paragraph IV Certification to a Paragraph Certification III, which indicated its intent not to market its generic Oxaydo product in advance of our patent expiry.

On October 9, 2013, we announced that we had entered into distinct Settlement Agreements with each of Par and Impax, to settle our patent infringement action pending against them in the United States District Court for the District of Delaware. In the suit, we alleged that a generic Oxecta® product for which each of Par and Impax is separately seeking approval to market in the United States pursuant to an ANDA filing with the FDA infringes a U.S. patent owned by us. Par is the first filer of an ANDA for a generic Oxecta® product and is entitled to the 180-day first filer exclusivity under applicable law and FDA regulations.

Under the terms of the Settlement Agreement with Par, Par may launch its generic Oxecta® product in the U.S., through the grant of a non-exclusive, royalty-bearing license from us that would trigger on January 1, 2022. We currently have Orange Book patents that are due to expire between November 2023 and March 2025. In certain limited circumstances, our license to Par would become effective prior to January 1, 2022. Par is required to pay us royalties in the range of 10% to 15% of Par’s net profits from the sale of its generic Oxecta® product.

Under the Settlement Agreement with Impax, Impax may launch its generic Oxecta® product in the U.S., through the grant of a non-exclusive, royalty-free license from us that would trigger 180 days following the first sale of a generic Oxecta® product in the U.S. by an entity that is entitled to the 180 day first-filer exclusivity under applicable law and FDA regulations (or if no entity is entitled to such 180 day exclusivity period, the date on which a generic Oxecta® product is first sold in the U.S. or November 27, 2021, whichever date occurs first). In certain circumstances, our license to Impax would become effective prior to such time.

On May 8, 2014, we announced that we had entered into a Settlement Agreement with Ranbaxy Inc. to settle our patent infringement action pending in the United States District Court for the District of Delaware. In the suit, we alleged that a generic of our Oxaydo product for which Ranbaxy is seeking approval to market in the United States pursuant to an ANDA filed with the FDA infringes U.S. patents owned by us. The Settlement Agreement provides that Ranbaxy’s current generic of our Oxaydo product that is the subject of its ANDA filing does not infringe our Orange Book listed patents with the FDA. We have not provided Ranbaxy a license to our patents and we may re-commence patent infringement litigation against Ranbaxy if Ranbaxy changes the formulation of its current generic Oxaydo product.

On May 21, 2014, we announced that we had entered into a Settlement Agreement with Sandoz Inc. to settle our patent infringement action pending against Sandoz in the United States District Court for the District of Delaware. In the suit, we alleged that a generic of our Oxaydo product for which Sandoz is seeking approval to market in the United States pursuant to an ANDA filed with the FDA infringes a U.S. patent owned by us. Under the Settlement Agreement, Sandoz may launch its generic to the Oxaydo product in the U.S., through the grant of a non-exclusive license from us that would trigger 180 days following the first sale of a generic to the Oxaydo product in the U.S. by an entity that is entitled to the 180 day first-filer exclusivity under applicable law and FDA regulations (or if no entity is entitled to such 180 day exclusivity period, the date on which a generic to the Oxaydo product is first sold in the U.S). In certain circumstances, our license to Sandoz would become effective prior to such time. Sandoz is not obligated to pay us a royalty if its current formulation of its generic to the Oxaydo product is approved by the FDA. In the event Sandoz changes or modifies the structure of its generic Oxaydo product, or materially changes or modifies the amounts or type of any excipient used in the Sandoz formulation disclosed in its ANDA filing with the FDA as of July 30, 2013, Sandoz is required to pay us a royalty based upon the Net Profits (as defined in the Settlement Agreement) derived from the net sales of such changed or modified Sandoz generic Oxaydo product in the United States.

Notwithstanding the settlement of these prior infringement actions, it is possible that other generic manufacturers may also seek to launch a generic version of Oxaydo and challenge our patents. Any determination in such infringement actions that our patents covering our Aversion Technology and Oxaydo are invalid or unenforceable, in whole or in part, or that the products covered by generic sponsors’ ANDAs do not infringe our patents could have a material adverse effect on our operations and financial condition.

INVESTMENTS IN MARKETABLE SECURITIES

12 Months Ended

Dec. 31, 2014

Investments, Debt and Equity Securities [Abstract]

INVESTMENTS IN MARKETABLE SECURITIES

NOTE 4 – INVESTMENTS IN MARKETABLE SECURITIES

Investments in marketable securities consisted of the following:

	December 31, 2014		December 31, 2013
	(in millions)		(in millions)
Marketable securities:
Corporate bonds — maturing within 1 year	$	3.5	$	3.1
Corporate bonds — maturing after 1 year and through March 2017		2.8		6.8
Exchange-traded funds		5.0		3.8
Total marketable securities	$	11.3	$	13.7

The Company’s marketable securities are classified as available-for-sale and are recorded at fair value based on quoted market prices or net asset value using the specific identification method. The purchase cost of corporate bonds may include a purchase price premium or discount which will be amortized or accreted against earned interest income to the maturity date of the bond. Our investments are classified as current in the Company’s Consolidated Balance Sheets as they may be sold within one year in response to changes in market prices or interest rates, to realign our investment concentrations or to meet our working capital needs.

The following tables provide a summary of the fair value and unrealized gains (losses) related to the Company’s available-for-sale securities (in millions):

	December 31, 2014
	(in millions)
							Fair
	Cost		Gross Unrealized Gains		Gross Unrealized Losses		Value
Available-for-sale:
Corporate bonds	$	6.3	$	-	$	-	$	6.3
Exchange-traded funds		5.0		-		-		5.0
Total - Current	$	11.3	$	-	$	-	$	11.3

	December 31, 2013
	(in millions)
							Fair
	Cost		Gross Unrealized Gains		Gross Unrealized Losses		Value
Available-for-sale:
Corporate bonds	$	9.9	$	-	$	-	$	9.9
Exchange-traded funds		3.8		-		-		3.8
Total - Current	$	13.7	$	-	$	-	$	13.7

Fair Value Measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants. Fair values determined based on Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined based on Level 2 inputs utilize observable quoted prices for similar assets and liabilities in active markets and observable quoted prices for identical or similar assets in markets that are not very active. Fair values determined based on Level 3 inputs utilize unobservable inputs and include valuations of assets or liabilities for which there is little, if any, market activity. A financial asset or liability’s classification within the above hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

Our assets measured at fair value or disclosed at fair value on a recurring basis as at December 31, 2014 and 2013 consisted of the following (in millions):

	December 31, 2014
	(in millions)
	Total		Level 1		Level 2		Level 3
Assets:
Corporate bonds		6.3				6.3		-
Exchange-traded funds		5.0		5.0		-		-
Total	$	11.3	$	5.0	$	6.3	$	-

	December 31, 2013
	(in millions)
	Total		Level 1		Level 2		Level 3
Assets:
Corporate bonds		9.9		-		9.9		-
Exchange-traded funds		3.8	$	3.8	$	-	$	-
Total	$	13.7		3.8		9.9		-

Accumulated Other Comprehensive Income (Loss)

Unrealized gains or losses on marketable securities are recorded in accumulated other comprehensive income (loss). Accumulated other comprehensive income (loss) at December 31, 2014 consisted of unrealized losses on securities of $13 thousand. Accumulated other comprehensive income (loss) at December 31, 2013 consisted of unrealized gains on securities of $19 thousand.

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-Glossary Debt Security

-URI http://asc.fasb.org/extlink&oid=6509901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6379141&loc=d3e15032-111544

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27405-111563

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-Glossary Equity Security

-URI http://asc.fasb.org/extlink&oid=6511694

+ Details

INVENTORIES

12 Months Ended

Dec. 31, 2014

Inventory Disclosure [Abstract]

INVENTORIES

NOTE 5 – INVENTORIES

Inventories consist of both raw and packaging materials on our Oxaydo product and finished goods held for distribution and sale on our Nexafed product. During 2014 we purchased raw and packaging material inventories for $260 thousand from Pfizer on the Oxaydo product we reacquired from them. Inventories are stated at the lower of cost (first-in, first-out method) or market (net realizable value). We write down inventories to net realizable value based on forecasted demand and market conditions, which may differ from actual results.

We have recorded Nexafed deferred revenue of $0.35 million and $0.29 million at December 31, 2014 and 2013, respectively. The related cost of sales of $0.22 million and $0.19 million at December 31, 2014 and 2013, respectively, is reported in our balance sheet in the other current deferred assets account and excluded from the reported year end inventories. We will recognize both the revenue and cost of sales on these Nexafed shipments once the right of return no longer exists or adequate history and information becomes available to estimate product returns.

Our purchases of ingredients and other materials required in our development and clinical trial activities are expensed as incurred.

Inventories are summarized as follows:

	December 31,
	2014		2013
	(in thousands)
Raw and packaging materials	$	260	$	-
Finished goods		44		501
Total inventory		304		501
Less: inventory reserve for finished goods		( -)		( 250)
Net inventory	$	304	$	251

Our inventory reserve activity during the year ended December 31, 2014 and 2013 was as follows:

Inventory reserve
	2014		2013
	(in thousands)
Beginning of year	$	250	$	-
Reserve expense for finished goods		201		250
		451		250
Inventory write-offs		(451)		(-)
End of year	$	-	$	250

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details

PROPERTY, PLANT AND EQUIPMENT

12 Months Ended

Dec. 31, 2014

Property, Plant and Equipment [Abstract]

PROPERTY, PLANT AND EQUIPMENT

NOTE 6 – PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment are summarized as follows:

	December 31,
	2014		2013
	(in thousands)
Building and improvements	$	1,259	$	1,259
Scientific equipment		595		595
Computer hardware and software		252		252
Machinery and equipment		386		252
Land and improvements		162		162
Other personal property		70		70
Office equipment		27		27
		2,751		2,617
Less: accumulated depreciation		(1,794)		(1,676)
Total property, plant and equipment, net	$	957	$	941

Depreciation and amortization expense was approximately $0.1 million for each of the years ended December 31, 2014, 2013, and 2012.

- Definition

The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.

+ References+ Details

DEBT

12 Months Ended

Dec. 31, 2014

Debt Disclosure [Abstract]

DEBT

NOTE 8 – DEBT

On December 27, 2013, we entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC (“Oxford” or the “Lender”), for a term loan to the Company in the principal amount of $10.0 million (the “Term Loan”). The full principal amount of the Term Loan was funded on December 27, 2013. We are using the proceeds of the Loan Agreement for general working capital and to fund our business requirements. The Term Loan accrues interest at a fixed rate of 8.35% per annum (with a default rate of 13.35% per annum). The Company is required to make monthly interest-only payments until the April 1, 2015 (“Amortization Date”) and starting on the Amortization Date, the Company is required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize the Term Loan through the maturity date of December 1, 2018. All unpaid principal and accrued and unpaid interest with respect to the Term Loan is due and payable in full on December 1, 2018. As security for its obligations under the Loan Agreement, the Company granted Lender a security interest in substantially all of its existing and after-acquired assets, exclusive of its intellectual property assets. Pursuant to the Loan Agreement, the Company is not allowed to pledge its intellectual property assets to others.

The Company may voluntarily prepay the Term Loan in full, but not in part, and any prepayment is subject to a prepayment premium equal to 2% of the principal prepaid, if prepaid prior to December 27, 2015, and 1% of the principal prepaid if prepaid after December 27, 2015. In addition, at the maturity, termination or upon voluntary or mandatory prepayment of the Term Loan the Company must pay the Lender an additional one-time interest payment of $795 thousand. We will incur and accrue additional monthly interest expense over the term of the loan for this additional one-time interest payment using the loan’s effective cash interest rate.

The Company was obligated to pay customary lender fees and expenses, including a one-time facility fee of $50 thousand and the Lender’s expenses in connection with the Loan Agreement. Combined with the Company’s own expenses and a $100 thousand consulting placement fee, the Company incurred $231 thousand in deferred debt issue costs. We are amortizing these costs into interest expense over the term of the loan using the loan’s effective interest rate.

The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, limits or restrictions on the Company’s ability to incur liens, incur indebtedness, pay dividends, redeem stock, and merge or consolidate and dispose of assets. In addition, it contains customary events of default that entitles the Lender to cause any or all of the Company’s indebtedness under the Loan Agreement to become immediately due and payable. The events of default (some of which are subject to applicable grace or cure periods), include, among other things, non-payment defaults, covenant defaults, a material adverse change in the Company, bankruptcy and insolvency defaults and material judgment defaults.

Our debt is summarized below:

2014
(in thousands)
Debt	Current		Long-term		Total
Beginning of year	$	-	$	10,000	$	10,000
Principal payments		-		-		-
Classification		1,758		(1,758)		-
End of year	$	1,758	$	8,242	$	10,000

Debt Discount	Current		Long-term		Total
Beginning of year	$	-	$	(400)	$	(400)
Amortization expense		-		119		119
End of year	$	-	$	(281)	$	(281)

Debt, net	$	1,758	$	7,961	$	9,719

Upon the execution of the Loan Agreement on December 27, 2013, we issued to the Lender warrants to purchase an aggregate of up to 298 thousand shares of our common stock at an exercise price equal to $1.595 per share (the “Warrants”). We recorded $400 thousand as debt discount associated with the fair value of the Warrants and are amortizing it to interest expense over the term of the loan using the loan’s effective interest rate. The Warrants are immediately exercisable for cash or by net exercise and will expire December 27, 2020. The fair value of the warrants was determined using the Black-Scholes option-pricing model. Significant assumptions used in the Black-Scholes model were:

Expected dividend yield	0.0	%
Risk-free interest rate	2.4	%
Expected volatility	92	%
Expected term (years)	7

On January 7, 2015, we and Oxford entered into an amendment (the “Amendment”) to the Loan Agreement. Pursuant to the Amendment, (i) the exercise price of the warrant previously issued to the Lender to purchase 297,805 shares of our Common Stock was lowered from $1.595 to $0.504 per share (the average closing price of our common stock on Nasdaq for the 10 trading days preceding the date of the Amendment), (ii) we agreed to maintain a $2.5 million cash balance until such time as we have repaid $5 million in principal of the Term Loan, and (iii) the Lender consented to the terms of our Collaboration and License Agreement with Egalet relating to our Oxaydo product.

Our interest expense consisted of the following:

	2014		2013
	(in thousands)
Interest expense:
Secured Promissory notes	$	1,024	$	9
Debt discount		119		-
Debt issue costs		69		-
Total interest expense	$	1,212	$	9

The annual principal payments of the debt at December 31, 2014 are as follows:

	AnnualPrincipal Payments
	(in thousands)
2015	$	1,758
2016		2,522
2017		2,741
2018		2,979
Total	$	10,000

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References+ Details

COMMON STOCK WARRANTS

12 Months Ended

Dec. 31, 2014

Stockholders Equity Note [Abstract]

COMMON STOCK WARRANTS

NOTE 10 – COMMON STOCK WARRANTS

In connection with the issuance of the $10.0 million secured promissory notes in December 2013, we issued common stock purchase warrants (“warrants”) to acquire approximately 298 thousand shares of our common stock having an exercise price of $1.595 per share with an expiration date in December 2020. In August 2014, warrants exercisable for 1.9 million shares of our common stock with an exercise price of $3.40 per share expired unexercised. At December 31, 2014, we have total outstanding warrants exercisable for 298 thousand shares of our common stock having a weighted average exercise price of $1.595 per share with an expiration date in December 2020. In January 2015, the exercise price of these warrants was reduced to $0.504 per share. The warrants contain a cashless exercise feature.

Our warrant activity during the years ended December 31, 2014 and 2013 is shown below:

	December 31,
	2014				2013
			Weighted				Weighted
			Average				Average
	Number		Exercise		Number		Exercise
	(000’s)		Price		(000’s)		Price
Outstanding, beginning		2,154	$	3.15		1,856	$	3.40
Issued		-		-		298		1.60
Exercised		-		-		-		-
Expired		(1,856)		3.40		-		-
Outstanding, ending		298	$	1.60		2,154	$	3.15

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

EMPLOYEE BENEFIT PLANS

12 Months Ended

Dec. 31, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

EMPLOYEE BENEFIT PLANS

NOTE 11 – EMPLOYEE BENEFIT PLANS

401(k) and Profit-Sharing Plan

We have a 401(k) and Profit-Sharing Plan (the “Plan”) for our employees. Employees may elect to make a basic contribution of up to 80% of their annual earnings subject to certain regulatory restrictions on their total contribution. The Plan provides that the Company can make discretionary matching contributions along with a discretionary profit-sharing contribution. We did not contribute matching or profit sharing contributions for the Plan in years 2014, 2013, and 2012.

Stock Option Plans

We maintain various stock option plans. A summary of our stock option plans as of December 31, 2014, 2013, and 2012 and for the years then ended consisted of the following:

	Years Ended December 31,
	2014				2013				2012
	(in thousands except price data)
			Weighted				Weighted				Weighted
			Average				Average				Average
			Exercise				Exercise		Number of		Exercise
	Number of Options		Price		Number of Options		Price		Options)		Price
Outstanding, beginning		3,738	$	4.99		3,296	$	5.50		3,556	$	6.41
Granted		900		0.52		548		1.66		475		2.80
Exercised		(31)		1.30		(31)		1.30		(31)		1.30
Forfeited or expired		(51)		3.50		(75)		5.02		(704)		8.43
Outstanding, ending		4,556	$	4.14		3,738	$	4.99		3,296	$	5.50
Options exercisable		3,476	$	5.21		3,115	$	5.61		2,763	$	5.99

The following table summarizes information about nonvested stock options outstanding at December 31, 2014:

			Weighted Average
	Number of		Fair
	Options Not Exercisable		Value
	(in thousands except per price data)
Outstanding at December 31, 2013		623	$	1.71
Granted		900		0.46
Vested		(443)		1.73
Forfeited		-		-
Outstanding at December 31, 2014		1,080	$	0.66

We estimate the option’s fair value on the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero, as we have not paid any cash dividends) and employee exercise behavior. Expected volatilities utilized in the Black-Scholes model are based on the historical volatility of our common stock price. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected life of the grants is derived from historical exercise activity. Historically, the majority of our stock options have been held until their expiration date.

The assumptions used in the Black-Scholes model to determine fair value for the 2014, 2013 and 2012 stock option grants were:

		2014			2013			2012
Expected dividend yield		0.0	%		0.0	%		0.0	%
Risk-free interest rates		2.2	%		1.9% to 2.9	%		1.7% to 2.0	%
Average expected volatility		97	%		111	%		114	%
Expected term (years)		10			10			10
Weighted average grant date fair value	$	0.46		$	1.54		$	2.60

As of December 31, 2014, there was no intrinsic value of the option awards which were vested and outstanding. As of December 31, 2013 and 2012 the aggregate intrinsic value of the option awards which were vested and outstanding was $13 thousand and $0.1 million, respectively. In addition, the aggregate intrinsic value of option awards exercised during the year ended December 31, 2014, 2013 and 2012 was $0.00, $28 thousand and $0.1 million, respectively. The total remaining unrecognized compensation cost on unvested option awards outstanding at December 31, 2014 was $0.8 million and is expected to be recognized in operating expense in varying amounts over the twenty-three months remaining in the requisite service period.

Information about the cashless stock option exercises during the last three years is as follows:

During 2014, options to purchase 24 thousand shares of common stock were exercised utilizing various cashless exercise features of our stock option plan and after withholding 16 thousand shares for $32 in exercise costs and withholding 2 thousand shares for $4 in statutory minimum withholding payroll taxes, we issued 6 thousand shares of common stock.

During 2013, options to purchase 24 thousand shares of common stock were exercised utilizing various cashless exercise features of our stock option plan and after withholding 17 thousand shares for $32 in exercise costs and withholding 1 thousand shares for $4 in statutory minimum withholding payroll taxes, we issued 6 thousand shares of common stock.

During 2012, options to purchase 24 thousand shares of common stock were exercised utilizing various cashless exercise features of the stock option plan and after withholding 10 thousand shares for $31 in exercise costs and withholding 5 thousand shares for $15 in statutory minimum payroll taxes, we issued 9 thousand shares of common stock.

Restricted Stock Unit Award Plan

We have two Restricted Stock Unit Award Plans for our employees and non-employee directors, a 2005 Restricted Stock Unit Award Plan (the “2005 RSU Plan”) and a 2014 Restricted Stock Unit Award Plan (the “2014 RSU Plan”). Vesting of an RSU entitles the holder to receive a share of our common stock on a distribution date. The share-based compensation cost to be incurred on a granted RSU is the RSU’s fair value, which is the market price of our common stock on the date of grant, less its exercise cost. The compensation cost is amortized to expense over the vesting period of the RSU award.

A summary of the grants under the RSU Plans as of December 31, 2014, 2013, and 2012, and for the years then ended consisted of the following (in thousands):

	Years Ended December 31,
	2014				2013				2012
	(in thousands)
									Number of
	Number of RSUs		Number of Vested RSUs		Number of RSUs		Number of Vested RSUs		RSUs		Number of Vested RSUs
Outstanding, beginning		829		829		1,658		1,658		2,487		2,487
Granted		147		147		-		-		-		-
Distributed		(829)		(829)		(829)		(829)		(829)		(829)
Vested		-		-		-		-		-		-
Forfeited or expired		-		-		-		-		-		-
Outstanding, ending		147		147		829		829		1,658		1,658

2005 Restricted Stock Unit Award Plan

Under our 2005 RSU Plan, one-fourth of vested shares of common stock underlying RSU awards of 3.3 million shares were distributed (after payment of exercise costs of $0.01 par value per share) on January 1 of each of years 2011 thru 2014. All RSUs granted under the 2005 RSU Plan had been distributed effective January 1, 2014.

Information about the distribution of 0.83 million shares under the 2005 RSU Plan during each of the last three years are as follows:

On January 1, 2014, 0.51 million shares were distributed to the holders while 0.32 million shares were withheld by the Company upon elections made to exchange RSUs in satisfaction of $0.5 million withholding tax obligations; and

On January 1, 2013, 0.51 million shares were distributed to the holders while 0.32 million shares were withheld by the Company upon elections made to exchange RSUs in satisfaction of $0.7 million withholding tax obligations.

On January 1, 2012, 0.53 million shares were distributed to the holders while 0.30 million shares were withheld by the Company upon elections made to exchange RSUs in satisfaction of $1.0 million withholding tax obligations.

2014 Restricted Stock Unit Award Plan

Our 2014 RSU Plan was approved by shareholders on May 1, 2014 and permits the grant of up to 2.0 million shares of our common stock pursuant to awards under the 2014 RSU Plan.

Information about the RSU grants under the 2014 RSU Plan is as follows:

On May 1, 2014, we awarded 37 thousand RSUs to each of our 4 non-employee directors. Such RSU awards vested 50% on June 30, 2014 and 25% on each of September 30 and December 31, 2014. Such non-employee director awards allow for non-employee directors to receive payment in cash, instead of stock, for up to 40% of each RSU award. The RSU awards subject to cash settlement are recorded as a liability in the Company’s balance sheet. The liability was $26 thousand at December 31, 2014. Accordingly the vested portion of the awards containing the cash settlement feature are being marked-to-market each reporting period until they are distributed. Marked-to-market accounting can create fluctuations in our compensation expense including the need to record additional expense. RSU awards are generally distributed on the first business day of the year after vesting, but such distribution can be deferred until a later date at the election of the non-employee director.

On January 2, 2015, we awarded 52 thousand RSUs to each of our 4 non-employee directors which also allow for them to receive payment in cash, instead of stock, for up to 40% of each RSU award. Such awards vest 25% at the end of each calendar quarter in 2015. The RSU awards subject to cash settlement are subject to marked-to market accounting. Distributions of stock under the January 2, 2015 award cannot be deferred until a later date and the stock under such awards will be distributed on January 4, 2016.

Information about the distribution of shares under the 2014 RSU Plan is as follows:

On January 2, 2015, 129 thousand RSUs from the May 1, 2014 award were distributed and 18 thousand RSUs were deferred until a future distribution date. Of the 129 thousand RSUs distributed, 99 thousand RSUs were distributed in common stock and 30 thousand RSUs were settled in cash.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References+ Details

INCOME TAXES

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 12 – INCOME TAXES

Provision for Income Taxes

The reconciliation between our provision for income taxes and the amounts computed by multiplying our loss before taxes by the U.S. statutory tax rate is as follows:

	December 31,
	2014		2013		2012
	(in thousands)
Benefit at U.S. statutory 34% tax rate	$	(4,491)	$	(4,690)	$	(3,287)
State taxes (benefit), net of federal effect		65		(238)		-
Research and development tax credits		(30)		(185)		-
Share-based compensation		262		369		473
Other		2		2		2
Change in valuation allowance		4,192		4,742		2,812
Provision for income taxes	$	-	$	-	$	-

Deferred Tax Assets and Valuation Allowance

Deferred tax assets reflect the tax effects of net operating losses (“NOLs”), tax credit carryovers, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The most significant item of our deferred tax assets is derived from our Federal NOLs. We have approximately $51.5 million federal income tax benefits at December 31, 2014 derived from $151.4 million Federal NOLs at the U.S. statutory tax rate of 34% and $2.9 million state NOLs, available to offset future taxable income, some of which have limitations for use as prescribed under IRC Section 382. Our Federal and state NOLs will expire in varying amounts between 2016 and 2034 if not used, and those expirations will cause fluctuations in our valuation allowances. In 2013 we adjusted the estimated future value of NOLs under IRC Section 382 resulting in increasing those NOLs by $15.5 million with an equally offsetting valuation allowance. The net change in the valuation allowance in 2014, 2013, and 2012 was approximately $2.4 million, $18.0 million, and $2.8 million, respectively.

As of December 31, 2014 we had federal research and development tax credits of approximately $1.1 million, which expire in the years 2024 through 2034. We also had approximately $0.3 million of Indiana state research and development tax credits, which expire in the years 2015 through 2017. The components of our deferred tax assets are as follows:

	December 31,
	2014		2013
	(in thousands)
Deferred tax assets:
Estimated future value of NOLs
- Federal	$	51,503	$	46,830
- State		2,898		2,843
Research and development tax credits		1,398		1,433
Share-based compensation		45		2,261
Other, net		151		119
Total deferred taxes		55,995		53,486
Valuation allowance		(55,995)		(53,486)
Net deferred tax assets	$	-	$	-

Realization of deferred tax assets is dependent upon future earnings, if any, and the timing and amount of which may be uncertain. Valuation allowances are placed on deferred tax assets when uncertainty exists on their near term utilization. We make periodic reviews of our valuation allowances and fluctuations can occur. Those fluctuations may be reflected as income tax expenses or benefits in the period they occur. We continue to maintain full valuation allowance against all of our deferred tax assets at December 31, 2014 due to uncertainties with respect to future utilization of net operating loss carryforwards. If in the future it is determined that amounts of our deferred tax assets would likely be realized, the valuation allowance would be reduced in the period in which such determination is made and a benefit from income taxes in such period would be recognized.

Uncertainty in Income Taxes

We adopted FASB’s statement regarding accounting for uncertainty in income taxes which defined the threshold for recognizing the benefits of tax-return positions in the financial statements as "more-likely-than-not" to be sustained by the taxing authorities. Our adoption of the standard did not result in establishing a contingent tax liability reserve or a corresponding charge to retained earnings. At each of December 31, 2014, 2013 and 2012 we had no liability for income tax associated with uncertain tax positions. If in the future we establish a contingent tax liability reserve related to uncertain tax positions, our practice will be to recognize the interest in interest expense and the penalties in other non-operating expense.

The Company files federal and state income tax returns and in the normal course of business the Company is subject to examination by these taxing authorities. As of December 31, 2014, the Company’s tax years 2011, 2012 and 2013 are subject to examination by the taxing authorities. With few exceptions, we believe the Company is no longer subject to U.S. federal, state and local examinations by taxing authorities for years before 2011. As of December 31, 2013 the Company’s tax year of 2010 was included in the tax years subject to examination.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References+ Details

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 13 – COMMITMENTS AND CONTINGENCIES

Facility Lease

The Company leases administrative office space in Palatine, Illinois under a lease expiring March 31, 2016 for approximately $25 thousand annually.

Reglan®/Metoclopramide Litigation

Halsey Drug Company, as predecessor to us, has been named along with numerous other companies as a defendant in cases filed in three separate state coordinated litigations pending in Pennsylvania, New Jersey and California, respectively captioned In re: Reglan®/Metoclopramide Mass Tort Litigation, Philadelphia County Court of Common Pleas, January Term, 2010, No. 01997; In re: Reglan Litigation, Superior Court of New Jersey, Law Division, Atlantic County, Case No. 289, Master Docket No. ATL-L-3865-10; and Reglan/Metoclopramide Cases, Superior Court of California, San Francisco County, Judicial Council Coordination Proceeding No. 4631, Superior Court No.: CJC-10-004631. In addition, Acura was served with a similar complaint by two individual plaintiffs in Nebraska federal court, which plaintiffs voluntarily dismissed in December 2014. In this product liability litigation against numerous pharmaceutical product manufacturers and distributors, including us, plaintiffs claim injuries from their use of the Reglan brand of metoclopramide and generic metoclopramide.

In the Pennsylvania action, over 200 lawsuits have been filed against us and Halsey Drug Company alleging that plaintiffs developed neurological disorders as a result of their use of the Reglan brand and/or generic metoclopramide. In the New Jersey action, plaintiffs filed approximately 150 lawsuits against us, but served less than 50 individual lawsuits upon us. In the California action, there are 89 pending cases against us, with more than 445 individual plaintiffs.

In the lawsuits filed to date, plaintiffs have not confirmed they ingested any of the generic metoclopramide manufactured by us. We discontinued manufacture and distribution of generic metoclopramide more than 19 years ago. In addition, we believe the June 23, 2011 decision by the U.S. Supreme Court in PLIVA v. Mensing (“Mensing decision”) holding that state tort law failure to warn claims against generic drug companies are pre-empted by the 1984 Hatch-Waxman Act Amendments and federal drug regulations will assist us in favorably resolving these cases. We have consistently maintained the position that these claims are without merit and intend to vigorously defend these actions.

In New Jersey, Generic Defendants, including Acura, filed dispositive motions based on the Mensing decision, which the Court granted with a limited exception. As of September 2012, the New Jersey trial court dismissed Acura with prejudice. In Pennsylvania, and California, Generic Defendants, including Acura, also filed dispositive motions based on the Mensing decision.

In Pennsylvania, on November 18, 2011, the trial court denied Generic Defendants’ dispositive preemption motions. On appeal, the Pennsylvania Superior Court held in a July 29, 2013 decision that federal preemption applied, but that Mensing did not completely bar all claims and refused to dismiss these cases. On September 17, 2014, the Pennsylvania Supreme Court declined to hear a further appeal. On December 16, 2014, Generic Defendants filed a Petition for a Writ of Certiorari requesting that the United States Supreme Court agree to hear a further appeal on the grounds that federal preemption under Mensing should completely bar all of these claims. All trial court proceedings have been stayed pending resolution of this lengthy appeal process. To the extent that plaintiffs intend to pursue their claims in the future, if the appeal is denied, Acura nonetheless remains optimistic that most, if not all, of these Philadelphia cases will eventually be dismissed against us based upon the favorable aspects of the Superior Court’s narrow preemption ruling and lack of product identification, although there can be no assurance in this regard. Legal fees related to this matter are currently covered by our insurance carrier.

In California, the trial court entered a May 25, 2012 Order denying Generic Defendants’ dispositive preemption motions. The Generics Defendants’ appeals from this order were denied by the California appellate courts. Therefore, subject to further developments, plaintiffs may be permitted to proceed with these lawsuits including state law claims based on (1) failing to communicate warnings to physicians through “Dear Doctor” letters; and (2) failure to update labeling to adopt brand labeling changes. California trial court also has acknowledged the preemptive effect of Mensing so that any claim “that would render the generic defendants in violation of federal law if they are found responsible under a state law cause of action, would not be permissible.” To date, however, none of these plaintiffs have confirmed they ingested any of the generic metoclopramide manufactured by us. Therefore, we expect the number of plaintiffs with possible claims to be reduced voluntarily or by motion practice. Action will be taken in an effort to dismiss Acura from these cases, although there can be no assurance in this regard. Legal fees related to this matter are currently covered by our insurance carrier.

As any potential loss is neither probable nor estimable, we have not accrued for any potential loss related to these matters as of December 31, 2014 and we are presently unable to determine if any potential loss would be covered by our insurance carrier.

- Definition

The entire disclosure for commitments and contingencies.

+ References+ Details

SELECTED QUARTERLY FINANCIAL DATA

12 Months Ended

Dec. 31, 2014

Quarterly Financial Information Disclosure [Abstract]

SUPPLEMENTARY DATA

SUPPLEMENTARY DATA (UNAUDITED)

Selected unaudited quarterly consolidated financial data is shown below (in thousands except per share amounts):

	For Three Month Periods Ended
	Mar. 31,		June 30,		Sept. 30,		Dec. 31,
	2014		2014		2014		2014
Net revenues (i)	$	42	$	35	$	145	$	529
Operating expenses		3,868		3,307		2,791		2,984

Operating loss		(3,826)		(3,272)		(2,646)		(2,455)
Net loss	$	(4,088)	$	(3,521)	$	(2,904)	$	(2,696)

Basic loss per share	$	(0.08)	$	(0.07)	$	(0.06)	$	(0.06)
Diluted loss per share	$	(0.08)	$	(0.07)	$	(0.06)	$	(0.06)

	For Three Month Periods Ended
	Mar. 31,		June 30,		Sept. 30,		Dec. 31,
	2013		2013		2013		2013
Net revenues (i)	$	4	$	1	$	83	$	35
Operating expenses		4,248		3,141		3,308		3,516

Operating loss		(4,244)		(3,140)		(3,225)		(3,481)
Net loss	$	(4,218)	$	(3,076)	$	(3,190)	$	(3,417)

Basic loss per share	$	(0.09)	$	(0.07)	$	(0.07)	$	(0.07)
Diluted loss per share	$	(0.09)	$	(0.07)	$	(0.07)	$	(0.07)

(i) See Note 2 for revenue recognition.

- Definition

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

+ References+ Details

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Reclassifications

Reclassifications

Certain reclassifications have been made to the prior years' amounts to conform to the current year's presentation.

Management Estimates

Management Estimates

Cash and Cash Equivalents

Cash and Cash Equivalents

Marketable Securities

Marketable Securities

Fair Value of Other Financial Instruments

Fair Value of Other Financial Instruments

Concentration of Credit Risk

Concentration of Credit Risk

Sales to certain of our customers during 2014 and 2013 accounting for 10% or more of our annual product sales, whether the product shipment was recognized or deferred, are presented below:

Customer	2014
Rite Aid Corporation		28	%
Cardinal Health, Inc.		24	%
AmerisourceBergen Corporation		13	%
McKesson Corporation		13	%
Kroger Foods		11	%

	2013
Rite Aid Corporation		52	%
Cardinal Health, Inc.		15	%

Accounts receivable from certain of our customers at December 31, 2014 and 2013 accounting for 10% or more of our gross accounts receivable are presented below:

Customer	2014
Kroger Foods		13	%
Rite Aid Corporation		83	%

	2013
Rite Aid Corporation		95	%

Inventories

Inventories

Property, Plant and Equipment

Property, Plant and Equipment

Depreciation expense is recorded on a straight-line basis over the estimated useful lives of the related assets. The estimated useful lives of the major classification of depreciable assets are:

Building and improvements		10 - 40 years
Land and improvements		20 - 40 years
Machinery and equipment		7 - 10 years
Scientific equipment		5 - 10 years
Computer hardware and software		3 - 10 years

Debt Issuance Costs and Debt Discount

Debt Issuance Costs and Debt Discount

Revenue Recognition

Revenue Recognition

Royalty Revenue

Royalty Revenue

Product Sales

Product Sales

License Fees

License Fees

Advertising Costs

Advertising Costs

The Company records the cost of its advertising efforts when services are performed or goods are delivered.

Shipping and Handling Costs

Shipping and Handling Costs

The Company records shipping and handling costs in selling expenses. The amounts recorded from the sales of Nexafed® were not material.

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

Research and Development Activities

Research and Development Activities

Share-based Compensation

Share-based Compensation

We have several share-based compensation plans covering stock options and RSUs for our employees and directors, which are described more fully in Note 11.

Our share-based compensation expense recognized in the Company’s results of operations comprised the following:

	Year ended December 31,
	2014		2013		2012
	(in thousands)
Research and development:
Stock option awards	$	220	$	315	$	375
RSU awards		-		-		-
	$	220	$	315	$	375

Selling, general and administrative:
Stock option awards		550		900		1,358
RSU awards		146		-		-
	$	696	$	900	$	1,358

Total share-based compensation expense	$	916	$	1,215	$	1,733

Comprehensive Income (Loss)

Comprehensive Income (Loss)

Income Taxes

Income Taxes

Earnings Per Share (“EPS”)

Earnings Per Share (“EPS”)

A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following:

	Years ended December 31,
	2014		2013		2012

	(in thousands except per share data)
EPS - basic
Numerator: net loss	$	(13,209)	$	(13,901)	$	(9,668)
Denominator:
Common shares		48,847		46,935		45,863
Vested RSUs		46		829		1,658
Basic weighted average shares outstanding		48,893		47,764		47,521
EPS - basic	$	(0.27)	$	(0.29)	$	(0.20)

EPS – assuming dilution
Numerator: net loss	$	(13,209)	$	(13,901)	$	(9,668)
Denominator:
Common shares		48,847		46,935		45,863
Vested RSUs		46		829		1,658
Stock options		-		-		-
Common stock warrants		-		-		-
Diluted weighted average shares outstanding		48,893		47,764		47,521
EPS - diluted	$	(0.27)	$	(0.29)	$	(0.20)

Excluded dilutive securities:
Common stock issuable:
Stock options		4,556		3,738		3,296
Common stock warrants		298		2,154		1,856
Total excluded potentially dilutive shares		4,854		5,892		5,152

Recent Accounting Pronouncements

Recent Accounting Pronouncements

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Concentration of Risk, by Risk Factor

Sales to certain of our customers during 2014 and 2013 accounting for 10% or more of our annual product sales, whether the product shipment was recognized or deferred, are presented below:

Customer	2014
Rite Aid Corporation		28	%
Cardinal Health, Inc.		24	%
AmerisourceBergen Corporation		13	%
McKesson Corporation		13	%
Kroger Foods		11	%

	2013
Rite Aid Corporation		52	%
Cardinal Health, Inc.		15	%

Accounts receivable from certain of our customers at December 31, 2014 and 2013 accounting for 10% or more of our gross accounts receivable are presented below:

Customer	2014
Kroger Foods		13	%
Rite Aid Corporation		83	%

	2013
Rite Aid Corporation		95	%

Estimated Lives of Major Classification of Depreciable Assets

The estimated useful lives of the major classification of depreciable assets are:

Building and improvements		10 - 40 years
Land and improvements		20 - 40 years
Machinery and equipment		7 - 10 years
Scientific equipment		5 - 10 years
Computer hardware and software		3 - 10 years

Non-Cash Share-Based Compensation Expense

Our share-based compensation expense recognized in the Company’s results of operations comprised the following:

	Year ended December 31,
	2014		2013		2012
	(in thousands)
Research and development:
Stock option awards	$	220	$	315	$	375
RSU awards		-		-		-
	$	220	$	315	$	375

Selling, general and administrative:
Stock option awards		550		900		1,358
RSU awards		146		-		-
	$	696	$	900	$	1,358

Total share-based compensation expense	$	916	$	1,215	$	1,733

Computation of Diluted Earnings (loss) Per Share

A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following:

	Years ended December 31,
	2014		2013		2012

	(in thousands except per share data)
EPS - basic
Numerator: net loss	$	(13,209)	$	(13,901)	$	(9,668)
Denominator:
Common shares		48,847		46,935		45,863
Vested RSUs		46		829		1,658
Basic weighted average shares outstanding		48,893		47,764		47,521
EPS - basic	$	(0.27)	$	(0.29)	$	(0.20)

EPS – assuming dilution
Numerator: net loss	$	(13,209)	$	(13,901)	$	(9,668)
Denominator:
Common shares		48,847		46,935		45,863
Vested RSUs		46		829		1,658
Stock options		-		-		-
Common stock warrants		-		-		-
Diluted weighted average shares outstanding		48,893		47,764		47,521
EPS - diluted	$	(0.27)	$	(0.29)	$	(0.20)

Excluded dilutive securities:
Common stock issuable:
Stock options		4,556		3,738		3,296
Common stock warrants		298		2,154		1,856
Total excluded potentially dilutive shares		4,854		5,892		5,152

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References+ Details

INVESTMENTS IN MARKETABLE SECURITIES (Tables)

12 Months Ended

Dec. 31, 2014

Investments, Debt and Equity Securities [Abstract]

Marketable securities

Investments in marketable securities consisted of the following:

	December 31, 2014		December 31, 2013
	(in millions)		(in millions)
Marketable securities:
Corporate bonds — maturing within 1 year	$	3.5	$	3.1
Corporate bonds — maturing after 1 year and through March 2017		2.8		6.8
Exchange-traded funds		5.0		3.8
Total marketable securities	$	11.3	$	13.7

Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value

The following tables provide a summary of the fair value and unrealized gains (losses) related to the Company’s available-for-sale securities (in millions):

	December 31, 2014
	(in millions)
							Fair
	Cost		Gross Unrealized Gains		Gross Unrealized Losses		Value
Available-for-sale:
Corporate bonds	$	6.3	$	-	$	-	$	6.3
Exchange-traded funds		5.0		-		-		5.0
Total - Current	$	11.3	$	-	$	-	$	11.3

	December 31, 2013
	(in millions)
							Fair
	Cost		Gross Unrealized Gains		Gross Unrealized Losses		Value
Available-for-sale:
Corporate bonds	$	9.9	$	-	$	-	$	9.9
Exchange-traded funds		3.8		-		-		3.8
Total - Current	$	13.7	$	-	$	-	$	13.7

Fair Value, Assets Measured on Recurring Basis

Our assets measured at fair value or disclosed at fair value on a recurring basis as at December 31, 2014 and 2013 consisted of the following (in millions):

	December 31, 2014
	(in millions)
	Total		Level 1		Level 2		Level 3
Assets:
Corporate bonds		6.3				6.3		-
Exchange-traded funds		5.0		5.0		-		-
Total	$	11.3	$	5.0	$	6.3	$	-

	December 31, 2013
	(in millions)
	Total		Level 1		Level 2		Level 3
Assets:
Corporate bonds		9.9		-		9.9		-
Exchange-traded funds		3.8	$	3.8	$	-	$	-
Total	$	13.7		3.8		9.9		-

- Definition

Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.

+ References+ Details

INVENTORIES (Tables)

12 Months Ended

Dec. 31, 2014

Inventory Disclosure [Abstract]

INVENTORIES

Inventories are summarized as follows:

	December 31,
	2014		2013
	(in thousands)
Raw and packaging materials	$	260	$	-
Finished goods		44		501
Total inventory		304		501
Less: inventory reserve for finished goods		( -)		( 250)
Net inventory	$	304	$	251

Inventory Reserve

Our inventory reserve activity during the year ended December 31, 2014 and 2013 was as follows:

Inventory reserve
	2014		2013
	(in thousands)
Beginning of year	$	250	$	-
Reserve expense for finished goods		201		250
		451		250
Inventory write-offs		(451)		(-)
End of year	$	-	$	250

DEBT (Tables)

12 Months Ended

Dec. 31, 2014

Debt Disclosure [Abstract]

Schedule of Debt

Our debt is summarized below:

2014
(in thousands)
Debt	Current		Long-term		Total
Beginning of year	$	-	$	10,000	$	10,000
Principal payments		-		-		-
Classification		1,758		(1,758)		-
End of year	$	1,758	$	8,242	$	10,000

Debt Discount	Current		Long-term		Total
Beginning of year	$	-	$	(400)	$	(400)
Amortization expense		-		119		119
End of year	$	-	$	(281)	$	(281)

Debt, net	$	1,758	$	7,961	$	9,719

Schedule Of Fair Value Of Warrants

Significant assumptions used in the Black-Scholes model were:

Expected dividend yield	0.0	%
Risk-free interest rate	2.4	%
Expected volatility	92	%
Expected term (years)	7

Schedule of Interest Expense

Our interest expense consisted of the following:

	2014		2013
	(in thousands)
Interest expense:
Secured Promissory notes	$	1,024	$	9
Debt discount		119		-
Debt issue costs		69		-
Total interest expense	$	1,212	$	9

Schedule Of Long Term Debt Future Principal Payments Year

The annual principal payments of the debt at December 31, 2014 are as follows:

	AnnualPrincipal Payments
	(in thousands)
2015	$	1,758
2016		2,522
2017		2,741
2018		2,979
Total	$	10,000

COMMON STOCK WARRANTS (Tables)

12 Months Ended

Dec. 31, 2014

Stockholders Equity Note [Abstract]

COMMON STOCK WARRANTS

Our warrant activity during the years ended December 31, 2014 and 2013 is shown below:

	December 31,
	2014				2013
			Weighted				Weighted
			Average				Average
	Number		Exercise		Number		Exercise
	(000’s)		Price		(000’s)		Price
Outstanding, beginning		2,154	$	3.15		1,856	$	3.40
Issued		-		-		298		1.60
Exercised		-		-		-		-
Expired		(1,856)		3.40		-		-
Outstanding, ending		298	$	1.60		2,154	$	3.15

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References+ Details

EMPLOYEE BENEFIT PLANS (Tables)

12 Months Ended

Dec. 31, 2014

Summary Of Information About Non Vested Stock Options Disclosure Abstract [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity

A summary of our stock option plans as of December 31, 2014, 2013, and 2012 and for the years then ended consisted of the following:

	Years Ended December 31,
	2014				2013				2012
	(in thousands except price data)
			Weighted				Weighted				Weighted
			Average				Average				Average
			Exercise				Exercise		Number of		Exercise
	Number of Options		Price		Number of Options		Price		Options)		Price
Outstanding, beginning		3,738	$	4.99		3,296	$	5.50		3,556	$	6.41
Granted		900		0.52		548		1.66		475		2.80
Exercised		(31)		1.30		(31)		1.30		(31)		1.30
Forfeited or expired		(51)		3.50		(75)		5.02		(704)		8.43
Outstanding, ending		4,556	$	4.14		3,738	$	4.99		3,296	$	5.50
Options exercisable		3,476	$	5.21		3,115	$	5.61		2,763	$	5.99

Schedule of Nonvested Share Activity

The following table summarizes information about nonvested stock options outstanding at December 31, 2014:

			Weighted Average
	Number of		Fair
	Options Not Exercisable		Value
	(in thousands except per price data)
Outstanding at December 31, 2013		623	$	1.71
Granted		900		0.46
Vested		(443)		1.73
Forfeited		-		-
Outstanding at December 31, 2014		1,080	$	0.66

Schedule of fair value of the warrants

The assumptions used in the Black-Scholes model to determine fair value for the 2014, 2013 and 2012 stock option grants were:

		2014			2013			2012
Expected dividend yield		0.0	%		0.0	%		0.0	%
Risk-free interest rates		2.2	%		1.9% to 2.9	%		1.7% to 2.0	%
Average expected volatility		97	%		111	%		114	%
Expected term (years)		10			10			10
Weighted average grant date fair value	$	0.46		$	1.54		$	2.60

Schedule of Share-based Compensation, Restricted Stock Units Award Activity

A summary of the grants under the RSU Plans as of December 31, 2014, 2013, and 2012, and for the years then ended consisted of the following (in thousands):

	Years Ended December 31,
	2014				2013				2012
	(in thousands)
									Number of
	Number of RSUs		Number of Vested RSUs		Number of RSUs		Number of Vested RSUs		RSUs		Number of Vested RSUs
Outstanding, beginning		829		829		1,658		1,658		2,487		2,487
Granted		147		147		-		-		-		-
Distributed		(829)		(829)		(829)		(829)		(829)		(829)
Vested		-		-		-		-		-		-
Forfeited or expired		-		-		-		-		-		-
Outstanding, ending		147		147		829		829		1,658		1,658

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Provision for Income Taxes

The reconciliation between our provision for income taxes and the amounts computed by multiplying our loss before taxes by the U.S. statutory tax rate is as follows:

	December 31,
	2014		2013		2012
	(in thousands)
Benefit at U.S. statutory 34% tax rate	$	(4,491)	$	(4,690)	$	(3,287)
State taxes (benefit), net of federal effect		65		(238)		-
Research and development tax credits		(30)		(185)		-
Share-based compensation		262		369		473
Other		2		2		2
Change in valuation allowance		4,192		4,742		2,812
Provision for income taxes	$	-	$	-	$	-

Components Of Deferred Tax Assets

	December 31,
	2014		2013
	(in thousands)
Deferred tax assets:
Estimated future value of NOLs
- Federal	$	51,503	$	46,830
- State		2,898		2,843
Research and development tax credits		1,398		1,433
Share-based compensation		45		2,261
Other, net		151		119
Total deferred taxes		55,995		53,486
Valuation allowance		(55,995)		(53,486)
Net deferred tax assets	$	-	$	-

SELECTED QUARTERLY FINANCIAL DATA (Tables)

12 Months Ended

Dec. 31, 2014

Selected Quarterly Financial Information [Abstract]

Selected unaudited quarterly consolidated financial data

Selected unaudited quarterly consolidated financial data is shown below (in thousands except per share amounts):

	For Three Month Periods Ended
	Mar. 31,		June 30,		Sept. 30,		Dec. 31,
	2014		2014		2014		2014
Net revenues (i)	$	42	$	35	$	145	$	529
Operating expenses		3,868		3,307		2,791		2,984

Operating loss		(3,826)		(3,272)		(2,646)		(2,455)
Net loss	$	(4,088)	$	(3,521)	$	(2,904)	$	(2,696)

Basic loss per share	$	(0.08)	$	(0.07)	$	(0.06)	$	(0.06)
Diluted loss per share	$	(0.08)	$	(0.07)	$	(0.06)	$	(0.06)

	For Three Month Periods Ended
	Mar. 31,		June 30,		Sept. 30,		Dec. 31,
	2013		2013		2013		2013
Net revenues (i)	$	4	$	1	$	83	$	35
Operating expenses		4,248		3,141		3,308		3,516

Operating loss		(4,244)		(3,140)		(3,225)		(3,481)
Net loss	$	(4,218)	$	(3,076)	$	(3,190)	$	(3,417)

Basic loss per share	$	(0.09)	$	(0.07)	$	(0.07)	$	(0.07)
Diluted loss per share	$	(0.09)	$	(0.07)	$	(0.07)	$	(0.07)

(i) See Note 2 for revenue recognition.

Concentration of Risk by Risk Factor - (Detail)	12 Months Ended
Concentration of Risk by Risk Factor - (Detail)	Dec. 31, 2014	Dec. 31, 2013
Rite Aid Corporation \| Sales Revenue, Net
Concentration Risk [Line Items]
Concentration Risk, Percentage	28.00%	52.00%
Rite Aid Corporation \| Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	83.00%	95.00%
Cardinal Health, Inc. \| Sales Revenue, Net
Concentration Risk [Line Items]
Concentration Risk, Percentage	24.00%	15.00%
AmerisourceBergen Corporation \| Sales Revenue, Net
Concentration Risk [Line Items]
Concentration Risk, Percentage	13.00%
McKesson Corporation \| Sales Revenue, Net
Concentration Risk [Line Items]
Concentration Risk, Percentage	13.00%
Kroger Foods \| Sales Revenue, Net
Concentration Risk [Line Items]
Concentration Risk, Percentage	11.00%
Kroger Foods \| Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	13.00%

Estimated Useful Lives of the Major Classification of Depreciable Assets - (Detail)	12 Months Ended
	Dec. 31, 2014
Building and Building Improvements [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	40 years
Building and Building Improvements [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	10 years
Land Improvements [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	40 years
Land Improvements [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	20 years
Machinery and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	10 years
Machinery and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	7 years
Scientific Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	10 years
Scientific Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	5 years
Computer Hardware and Software [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	10 years
Computer Hardware and Software [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	3 years

Non-Cash Share-Based Compensation Expense (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation, Total	$ 890	$ 1,215	$ 1,733
Research and Development Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation, Total	220	315	375
Research and Development Expense \| Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation, Total	0	0	0
Research and Development Expense \| Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation, Total	220	315	375
Selling, General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation, Total	696	900	1,358
Selling, General and Administrative \| Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation, Total	146	0	0
Selling, General and Administrative \| Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation, Total	$ 550	$ 900	$ 1,358

Reconciliation of Numerators and Denominators of Basic and Diluted EPS (Detail) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
EPS - basic
Numerator: net loss	$ (2,696)	$ (2,904)	$ (3,521)	$ (4,088)	$ (3,417)	$ (3,190)	$ (3,076)	$ (4,218)	$ (13,209)	$ (13,901)	$ (9,668)
Denominator:
Common shares									48,847	46,935	45,863
Vested RSUs									46	829	1,658
Basic weighted average shares outstanding									48,893	47,764	47,521
EPS - basic	$ (0.06)	$ (0.06)	$ (0.07)	$ (0.08)	$ (0.07)	$ (0.07)	$ (0.07)	$ (0.09)	$ (0.27)	$ (0.29)	$ (0.20)
EPS - assuming dilution
Numerator: net loss	$ (2,696)	$ (2,904)	$ (3,521)	$ (4,088)	$ (3,417)	$ (3,190)	$ (3,076)	$ (4,218)	$ (13,209)	$ (13,901)	$ (9,668)
Denominator:
Common shares									48,847	46,935	45,863
Vested RSUs									46	829	1,658
Stock options									0	0	0
Common stock warrants									0	0	0
Diluted weighted average shares outstanding									48,893	47,764	47,521
EPS - diluted	$ (0.06)	$ (0.06)	$ (0.07)	$ (0.08)	$ (0.07)	$ (0.07)	$ (0.07)	$ (0.09)	$ (0.27)	$ (0.29)	$ (0.20)
Common shares issuable:
Total excluded common shares									4,854	5,892	5,152
Stock options
Common shares issuable:
Total excluded common shares									4,556	3,738	3,296
Common stock warrants
Common shares issuable:
Total excluded common shares									298	2,154	1,856

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended							0 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2014 Egalet Ltd [Member]	Dec. 31, 2014 Sales Revenue, Net [Member] Minimum [Member]	Dec. 31, 2013 Sales Revenue, Net [Member] Minimum [Member]	Dec. 31, 2014 Accounts Receivable [Member] Minimum [Member]	Dec. 31, 2013 Accounts Receivable [Member] Minimum [Member]	Dec. 31, 2014 Purdue Pharma [Member]	Apr. 09, 2014 Pfizer [Member]	Dec. 31, 2014 Pfizer [Member] Raw Materials [Member]
Financing Receivable, Impaired [Line Items]
Deferred Revenue, Revenue Recognized	$ 400,000
Royalty Revenue, Total	4,000
Concentration Risk, Percentage			10.00%	10.00%	10.00%	10.00%
Payments to Suppliers									260,000
Litigation Settlement, Expense							$ 500,000
Contract Termination Claims, Description								Pfizer Agreement was terminated and the rights to Oxecta were returned to us after making a one-time payment of $2.0 million to Pfizer.
Loss Contingency, Settlement Agreement, Terms		Egalet paid us an upfront payment of $5 million upon signing of the Egalet Agreement

License, Development, and Commercialization Agreements - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014 Settlement Agreement With Par	Dec. 31, 2014 Pfizer Agreement	Dec. 31, 2014 Egalet Agreement	Dec. 31, 2014 Minimum Settlement Agreement With Par	Dec. 31, 2014 Maximum Settlement Agreement With Par
License Development and Commercialization Agreement [Line Items]
Percentage of royalty		5.00%		10.00%	15.00%
Payment for Termination		$ 2,000,000
Patents expiration year	expire between November 2023 and March 2025
Line of Credit Facility, Description			Egalet paid us an upfront payment of $5 million upon signing of the Egalet Agreement and will pay us a $2.5 million milestone on the earlier to occur of (A) the launch of Oxaydo and (B) January 1, 2016, but in no event earlier than June 30, 2015.
Minimum Net Sales Reaching Description			one-time $12.5 million milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year.
Agreement Termination Notice Description			Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalet’s launch of Oxaydo. Egalet also may terminate the Agreement prior to the launch of Oxaydo on 30 days prior written notice upon the occurrence of serious safety issues, regulatory restrictions and intellectual property issues, in each case involving Oxaydo.

Summary of Investments in Marketable Securities (Detail) (USD $) In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Marketable securities:
Corporate bonds — maturing within 1 year	$ 3.5	$ 3.1
Corporate bonds — maturing after 1 year and through March 2017	2.8	6.8
Total marketable securities	11.3	13.7
Exchange-traded funds
Marketable securities:
Total marketable securities	$ 5.0	$ 3.8

Available for Sale Securities Continuous Unrealized Loss Position Fair Value (Detail) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Available For Sale Securities Continuous Unrealized Loss Position Fair Value [Line Items]
Cost	$ 11.3	$ 13.7
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	11.3	13.7
Corporate Bonds
Available For Sale Securities Continuous Unrealized Loss Position Fair Value [Line Items]
Cost	6.3	9.9
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	6.3	9.9
Exchange-traded funds
Available For Sale Securities Continuous Unrealized Loss Position Fair Value [Line Items]
Cost	5.0	3.8
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	$ 5.0	$ 3.8

Assets Measured at Fair Value or Disclosed at Fair Value on Recurring Basis (Detail) (USD $) In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Assets:
Total marketable securities	$ 11.3	$ 13.7
Corporate bonds
Assets:
Total marketable securities	6.3	9.9
Exchange-traded funds
Assets:
Total marketable securities	5.0	3.8
Fair Value, Inputs, Level 1
Assets:
Total marketable securities	5.0	3.8
Fair Value, Inputs, Level 1 \| Corporate bonds
Assets:
Total marketable securities	0	0
Fair Value, Inputs, Level 1 \| Exchange-traded funds
Assets:
Total marketable securities	5.0	3.8
Fair Value, Inputs, Level 2
Assets:
Total marketable securities	6.3	9.9
Fair Value, Inputs, Level 2 \| Corporate bonds
Assets:
Total marketable securities	6.3	9.9
Fair Value, Inputs, Level 2 \| Exchange-traded funds
Assets:
Total marketable securities	0	0
Fair Value, Inputs, Level 3
Assets:
Total marketable securities	0	0
Fair Value, Inputs, Level 3 \| Corporate bonds
Assets:
Total marketable securities	0	0
Fair Value, Inputs, Level 3 \| Exchange-traded funds
Assets:
Total marketable securities	$ 0	$ 0

Schedule of Inventories (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Sep. 24, 2012
Inventory [Line Items]
Raw and packaging materials	$ 260	$ 0		$ 260
Finished goods	44	501
Total inventory	304	501
Less: inventory reserve for finished goods	0	(250)	0
Net inventory	$ 304	$ 251

- Definition

Amount of valuation reserve for inventory.

+ References+ Details

Inventory Reserve (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Inventory [Line Items]
Beginning of year	$ 250	$ 0
Reserve expense for finished goods	201	250
Inverntory valuation reserve gross	451	250
Inventory write-offs	(451)	0
End of year	$ 0	$ 250

- Definition

Amount of valuation reserve for inventory.

+ References+ Details

Inventories - Additional Information (Detail) (USD $)	12 Months Ended
Inventories - Additional Information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Sep. 24, 2012
Inventory [Line Items]
Cost of Goods Sold	$ 220,000	$ 190,000
Inventory, Raw Materials and Supplies, Gross	260,000	0	260,000
Deferred Revenue, Current	$ 353,000	$ 287,000

Property, Plant and Equipment (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 2,751	$ 2,617
Less: accumulated depreciation	(1,794)	(1,676)
Total property, plant and equipment, net	957	941
Building and improvements
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	1,259	1,259
Scientific equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	595	595
Computer hardware and software
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	252	252
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	386	252
Land and improvements
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	162	162
Other personal property
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	70	70
Office equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 27	$ 27

Accrued Expenses (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Accounts Payable and Accrued Liabilities [Line Items]
Professional services	$ 253	$ 293
Other fees and services	110	140
Payroll, payroll taxes and benefits	94	78
Clinical and regulatory services	83	0
Contract manufacture services	0	14
Property taxes	15	15
Franchise taxes	13	1
Total	$ 568	$ 541

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References+ Details

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References+ Details

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References+ Details

Summary of Debt (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Debt
Beginning of year	$ 10,000
Principal payments	0
Classification	0
End of year	10,000
Debt Discount
Beginning of year	400
Amortization expense	119
End of year	281
Debt, net	7,961	9,600
Long-term Debt [Member]
Debt
Beginning of year	10,000
Principal payments	0
Classification	(1,758)
End of year	8,242
Debt Discount
Beginning of year	(400)
Amortization expense	119
End of year	(281)
Debt, net	7,961
Short-term Debt [Member]
Debt
Beginning of year	0
Principal payments	0
Classification	1,758
End of year	1,758
Debt Discount
Beginning of year	0
Amortization expense	0
End of year	0
Debt, net	$ 1,758

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References+ Details

Fair Value of Warrants using the Black-Scholes option-pricing model - (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Fair Value Of Warrants [Line Items]
Expected dividend yield	0.00%	0.00%	0.00%
Risk-free interest rates	2.40%
Average expected volatility	92.00%	111.00%	114.00%
Expected term (years)	7 years	10 years	10 years

Interest Expense (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Interest expense:
Secured Promissory notes	$ 1,024	$ 9
Debt discount	119	0
Debt issue costs	69	0
Total interest expense	$ 1,212	$ 9	$ 0

Long-Term Debt (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
2015	$ 1,758
2016	2,522
2017	2,741
2018	2,979
Total	$ 10,000	$ 10,000

Debt - Additional Information (Detail) (USD $)	12 Months Ended					0 Months Ended		12 Months Ended
Debt - Additional Information (Detail) (USD $)	Dec. 31, 2014	Jan. 31, 2015	Aug. 30, 2014	Dec. 31, 2013	Dec. 27, 2013	Jan. 07, 2015 Subsequent Event [Member]	Jan. 07, 2015 Subsequent Event [Member] Minimum [Member]	Dec. 31, 2014 Warrant	Dec. 31, 2013 Warrant	Dec. 31, 2014 After December 27 2014 but on or prior to December 27, 2015	Dec. 31, 2014 After December 27 2015	Dec. 31, 2014 First Revenue Event Occurs
Debt Instrument [Line Items]
Debt instrument principal amount					$ 10,000,000
Debt instrument, interest rate, stated percentage	8.35%
Debt default long term debt percentage	13.35%
Debt Instrument, Maturity Date	Dec. 01, 2018
Debt instrument prepayment percentage										2.00%	1.00%
Debt instrument periodic payment terms balloon payment to be paid												795,000
Debt instrument, fee amount	50,000
Debt consulting placement fee	100,000
Debt related commitment fees and debt issuance costs	231,000
Debt instrument unamortized discount	281,000			400,000
Warrants to purchase common stock	298,000		1,900,000	298,000					298,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.595	$ 0.504	$ 3.40	$ 1.595		$ 1.595	$ 0.504		$ 1.595
Warrants, expiry date	December 2020							December 27, 2020	December 2020
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						297,805
Debt instrument Cash Maintenance						2,500,000
Repayments of Debt						$ 5,000,000

Equity Financing - Additional Information (Detail) (USD $) Share data in Millions, unless otherwise specified	1 Months Ended	12 Months Ended
	Apr. 18, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Equity Financing [Line Items]
Net offering costs			$ 102,000
Proceeds from 'at the market offering'		0	3,328,000	0
Proceeds from sale of common stock	13,000,000
Sales Agreement with MLV & Co
Equity Financing [Line Items]
Sale of stock number shares issued			1.94
Sale of Stock, Consideration Received on Transaction			$ 3,300,000

Common Stock Warrant Activity (Detail) (Warrant, USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Warrant
Number of Shares
Number of Options Outstanding, beginning	2,154	1,856
Issued	0	298
Exercised	0	0
Expired	(1,856)	0
Number of Options Outstanding, ending	298	2,154
Weighted Average Exercise Price
Weighted Average Exercise Price, beginning	$ 3.15	$ 3.40
Issued	$ 0	$ 1.60
Exercised	$ 0	$ 0
Expired	$ 3.40	$ 0
Weighted Average Exercise Price, ending	$ 1.60	$ 3.15

Common Stock Warrants - Additional Information (Detail) (USD $) In Millions, except Share data in Thousands, unless otherwise specified	12 Months Ended					12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jan. 31, 2015	Aug. 30, 2014	Jan. 07, 2015 Subsequent Event	Dec. 31, 2014 Warrant	Dec. 31, 2013 Warrant
Class of Warrant or Right [Line Items]
Common stock warrant exercisable outstanding, shares	298	298		1,900			298
Common stock Warrant expiration date	December 2020					December 27, 2020	December 2020
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.595	$ 1.595	$ 0.504	$ 3.40	$ 1.595		$ 1.595
Secured Debt		$ 10.0
Stock Issued During Period, Shares, Acquisitions		298
Share Price		$ 1.595

Stock Option Award Activity (Detail) (Stock Option Plan, USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock Option Plan
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, beginning	3,738	3,296	3,556
Number of Options, Granted	900	548	475
Number of Options, Exercised	(31)	(31)	(31)
Number of Options, Forfeited or expired	(51)	(75)	(704)
Number of Options Outstanding, ending	4,556	3,738	3,296
Number of Options exercisable	3,476	3,115	2,763
Weighted Average Exercise Price, beginning	$ 4.99	$ 5.50	$ 6.41
Weighted Average Exercise Price, Granted	$ 0.52	$ 1.66	$ 2.80
Weighted Average Exercise Price, Exercised	$ 1.30	$ 1.30	$ 1.30
Weighted Average Exercise Price, Forfeited or expired	$ 3.50	$ 5.02	$ 8.43
Weighted Average Exercise Price, ending	$ 4.14	$ 4.99	$ 5.50
Weighted Average Exercise Price, Options exercisable	$ 5.21	$ 5.61	$ 5.99

Summary of Information about Non Vested Stock Options (Detail) (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2014
Summary Of Information About Non Vested Stock Options Disclosure [Line Items]
Outstanding, beginning	623
Granted	900
Vested	(443)
Forfeited	0
Outstanding, ending	1,080
Outstanding beginning, Weighted Average Fair Value	$ 1.71
Granted, Weighted Average Fair Value	$ 0.46
Vested, Weighted Average Fair Value	$ 1.73
Forfeited, Weighted Average Fair Value	$ 0
Outstanding ending, Weighted Average Fair Value	$ 0.66

Assumptions Used in Black-Scholes Model to Determine Fair Value for Stock Option Awards Granted (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%	0.00%
Risk-free interest rates	2.40%
Average expected volatility	92.00%	111.00%	114.00%
Expected term (years)	7 years	10 years	10 years
Weighted average grant date fair value	$ 0.46	$ 1.54	$ 2.60
Maximum [Member]
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rates		2.90%	2.00%
Minimum [Member]
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rates		1.90%	1.70%

Summary of RSU Plan (Detail) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	623
Granted	900
Vested	443
Forfeited or expired	0
Outstanding, ending	1,080
Restricted Stock Units
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	829	1,658	2,487
Granted	147	0	0
Distributed	(829)	(829)	(829)
Vested	0	0	0
Forfeited or expired	0	0	0
Outstanding, ending	147	829	1,658
Vested Restricted Stock Units (RSUs)
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	829	1,658	2,487
Granted	147	0	0
Distributed	(829)	(829)	(829)
Vested	0	0	0
Forfeited or expired	0	0	0
Outstanding, ending	147	829	1,658

Employee Benefit Plans - Additional Information (Detail) (USD $)	12 Months Ended					1 Months Ended			12 Months Ended		0 Months Ended	2 Months Ended	3 Months Ended		12 Months Ended	8 Months Ended			0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014 401(k) and Profit-Sharing Plan	Dec. 31, 2014 Stock options	Jan. 31, 2014 Restricted Stock Units (RSUs) [Member]	Jan. 31, 2013 Restricted Stock Units (RSUs) [Member]	Jan. 31, 2012 Restricted Stock Units (RSUs) [Member]	Dec. 31, 2014 Restricted Stock Units (RSUs) [Member]	May 01, 2014 2014 Restricted Stock Unit Award Plan [Member]	May 01, 2014 2014 Restricted Stock Unit Award Plan [Member] Four Non Employee Directors [Member]	Jun. 30, 2014 2014 Restricted Stock Unit Award Plan [Member] Four Non Employee Directors [Member]	Dec. 31, 2014 2014 Restricted Stock Unit Award Plan [Member] Four Non Employee Directors [Member]	Sep. 30, 2014 2014 Restricted Stock Unit Award Plan [Member] Four Non Employee Directors [Member]	Dec. 31, 2014 2014 Restricted Stock Unit Award Plan [Member] Four Non Employee Directors [Member]	Jan. 02, 2015 2014 Restricted Stock Unit Award Plan [Member] Subsequent Event [Member]	Jan. 02, 2015 2014 Restricted Stock Unit Award Plan [Member] Subsequent Event [Member] Settled In Cash [Member]	Jan. 02, 2015 2014 Restricted Stock Unit Award Plan [Member] Subsequent Event [Member] Convertible Common Stock [Member]	Jan. 02, 2015 2014 Restricted Stock Unit Award Plan [Member] Subsequent Event [Member] Four Non Employee Directors [Member]
Employee Benefit Plans Disclosure [Line Items]
Maximum basic contribution percentage per employee on annual earnings				80.00%
Aggregate intrinsic value of the option awards vested	$ 0	$ 13,000	$ 100,000
Aggregate intrinsic value of option awards exercised	0.00	28,000	100,000
Unrecognized compensation cost on unvested option awards outstanding	800,000
Employee service share based compensation nonvested awards period					23 months
Common stock exercised in cashless exercise features	24,000	24,000	24,000
Withholding tax obligations	32	32	31
Statutory Minimum Payroll Taxes	4	4	15
Number Of Shares Issued On Cashless Exercises	6,000	6,000	9,000
Restricted Stock Units Sale Price	$ 0.01
Shares withheld upon elections made to exchange RSUs	830,000					320,000	320,000	300,000
Restricted Stock Units Exchanged In Satisfaction Of Withholding Tax Obligations						500,000	700,000	1,000,000
Number of vested shares distributed to holders	443,000					510,000	510,000	530,000
Common stock exercised in cashless exercise features withheld minimum payroll taxes	16,000	17,000	10,000
Common stock exercised in cashless exercise features withheld statutory minimum payroll taxes	2,000	1,000	5,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant										2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross											37,000								52,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage												50.00%	25.00%	25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Description											stock, for up to 40%								stock, for up to 40%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value															$ 26,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights									one-fourth of vested shares of common stock underlying RSU awards of 3.3 million shares were distributed (after payment of $0.01 par value per share) on January 1 of each of years 2011 thru 2014.										25
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period																129,000	30,000	99,000
Share Based Compensation Arrangement Share Based Payment Shares Reserved For Future Distribution																18,000

Provision for Income Taxes (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Provision For Income Taxes [Line Items]
Benefit at U.S. statutory 34% tax rate	$ (4,491)	$ (4,690)	$ (3,287)
State taxes (benefit), net of federal effect	65	(238)	0
Research and development tax credits	(30)	(185)	0
Share-based compensation	262	369	473
Other	2	2	2
Change in valuation allowance	4,192	4,742	2,812
Provision for income taxes	$ 0	$ 0	$ 0

Components of Our Deferred Tax Assets (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
- Federal	$ 51,503	$ 46,830
- State	2,898	2,843
Research and development tax credits	1,398	1,433
Share-based compensation	45	2,261
Other, net	151	119
Total deferred taxes	55,995	53,486
Valuation allowance	(55,995)	(53,486)
Net deferred tax assets	$ 0	$ 0

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
Income Taxes - Additional Information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Line Items]
Federal income tax benefits	$ 51,500,000
Federal NOLs	151,400,000
U.S. statutory tax rate	34.00%
Research and development tax credits	1,398,000	1,433,000
State income tax benefits	2,900,000
Valuation Allowance	15,500,000
Valuation allowance, deferred tax asset, change in amount	2,400,000	18,000,000	2,800,000
Federal Research and Development
Income Tax Disclosure [Line Items]
Research and development tax credits	1,100,000
Research and development expiration period	which expire in the years 2024 through 2034
Indiana State Research and Development
Income Tax Disclosure [Line Items]
Research and development tax credits	$ 300,000
Research and development expiration period	which expire in the years 2015 through 2017
Maximum
Income Tax Disclosure [Line Items]
NOL expiration year	2034
Minimum
Income Tax Disclosure [Line Items]
NOL expiration year	2016

Commitments and Contingencies - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014
Pennsylvania State
Commitments and Contingencies Disclosure [Line Items]
Number of lawsuits filed	200
New Jersey State
Commitments and Contingencies Disclosure [Line Items]
Number of lawsuits filed	150
Number of lawsuits served	50
California State
Commitments and Contingencies Disclosure [Line Items]
Number of plaintiffs served in a single complaint	445
Palatine Lllinois
Commitments and Contingencies Disclosure [Line Items]
Leases administrative office space	$ 25
Lease expiring date	lease expiring March 31, 2016

Schedule of Selected Quarterly Financial Data (Detail) (USD $)
In Thousands, except Per Share data, unless otherwise specified

3 Months Ended

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Schedule Of Quarterly Financial Information [Line Items]

Net revenues

$ 529

^[1]

$ 145

^[1]

$ 35

^[1]

$ 42

^[1]

$ 35

$ 83

$ 1

$ 4

Operating expenses

2,984

2,791

3,307

3,868

3,516

3,308

3,141

4,248

Operating loss

(2,455)

(2,646)

(3,272)

(3,826)

(3,481)

(3,225)

(3,140)

(4,244)

Net loss

$ (2,696)

$ (2,904)

$ (3,521)

$ (4,088)

$ (3,417)

$ (3,190)

$ (3,076)

$ (4,218)

EPS - basic

$ (0.06)

$ (0.07)

$ (0.08)

$ (0.07)

$ (0.09)

Diluted loss per share

$ (0.06)

$ (0.07)

$ (0.08)

$ (0.07)

$ (0.09)

[1]	See Note 2 for revenue recognition.

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References+ Details

Investments In Marketable Securities - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Investment In Marketable Securities [Line Items]
Unrealized gains on securities	$ (32)	$ 59	$ (40)